

GENES

This application is a continuation-in-part of U.S. Application Serial No. 10/621,911 filed July 17, 2003 as a continuation-in-part of International Application No. PCT/GB02/00215, filed January 18, 2002, which claims priority from UK Patent Application No. 0101300.2, filed January 18, 2001; and the present application is also a continuation in part of International Patent Application No. _____ filed July 17, 2003 (D Young & Co Attorney Docket No: P014694WO). All of the above referenced applications are herein incorporated by reference.

FIELD

10 The present invention relates to the fields of development, molecular biology and genetics. More particularly, the invention relates to genes which are expressed exclusively in the earliest populations of primordial germ cells (PGCs) and the use of such genes and the products thereof in identification of pluripotent and multipotent cells such as PGCs, pluripotent embryonic stem cells (ES) and
15 pluripotent embryonic germ cells (EG), in cell populations. They are also markers for a change in the state of cells from being non pluripotent to becoming pluripotent, and in being able to confer this state on a non pluripotent cell.

INTRODUCTION

20 Post fertilisation, the early mammalian embryo undergoes four rounds of cleavage to form a morula of 16 cells. These cells, following further rounds of division, develop into a blastocyst in which the cells can be divided into two distinct regions; the inner cell mass, which will form the embryo, and the trophectoderm, which will form extra-embryonic tissue, such as the placenta.

25 The cells that form part of the embryo up until the formation of the blastocyst are totipotent; in other words, each of the cells has the ability to give rise to a complete individual embryo, and to all the extra-embryonic tissues required for

its development. After blastocyst formation, the cells of the inner cell mass are no longer totipotent, but are pluripotent, in that they can give rise to a range of different tissues. A known marker for such cells is the expression of the enzyme alkaline phosphatase and *Oct4*.

5 Primordial germ cells (PGCs) are pluripotent cells that have the ability to differentiate into all three primary germ layers. In mammals, the PGCs migrate from the base of the allantois, through the hindgut epithelium and dorsal mesentery, to colonise the gonadal anlage. The PGC-derived cells have a characteristically low cytoplasm/nucleus ratio, usually with prominent nucleoli. PGCs may be isolated
10 from the embryos by removing the genital ridge of the embryo, dissociating the PGCs from the gonadal anlage, and collecting the PGCs. The earliest PGC population is reported to consist of a cluster of some 45 (forty-five) alkaline phosphatase positive cells, found at the base of the emerging allantois, 7.25 days post-fertilisation (Ginsburg *et al.*, (1990) Development 110:521-528).

15 PGCs have many applications in modern biotechnology and molecular biology. They are useful in the production of transgenic animals, where embryonic germ (EG) cells derived from PGCs may be used in much the same manner as embryonic stem (ES) cells (Labosky *et al.*, (1994) Development 120:3197-3204). Moreover, they are useful in the study of foetal development and the provision of
20 pluripotent stem cells for tissue regeneration in the therapy of degenerative diseases and repopulation of damaged tissue following trauma. Above all, PGCs while having some specialised properties, retain an underlying pluripotency, which is lost from the neighbouring cells that surround the founder population of PGCs that acquire a somatic cell fate. PGCs and the surrounding somatic cells share a common
25 ancestry. However, the founder PGCs are few in number and difficult to isolate from embryonic tissue and the surrounding somatic cells, which complicates their study and the development of techniques which make use thereof.

Little is known in the art about the expression of genes in the founder population of PGCs and the relationship between PGC-specific gene expression and

the retention of pluripotency in these cells. Certain markers for PGCs are known – for example, the expression of tissue non-specific alkaline phosphatase (TNAP) has been used as a marker for early PGCs (Ginsburg *et al.*, (1990) Development 110:521-528). Oct4 is known to be expressed in PGCs, but not somatic cells (Yoem *et al.*, (1996) Development 122:881-894). Other markers, such as BMP4, are known to be expressed primarily in somatic tissues (Lawson *et al.*, (1999) Genes & Dev. 13:424-436). However, none of these genes is specific for PGCs, since they are also expressed in other tissue types. There is therefore a need in the art for the identification of genes which may be used as markers for PGCs and which may provide an insight into the biology of germ cell development and the nature of the pluripotent state.

SUMMARY

We disclose the sequences of two genes which are expressed specifically in PGCs and other pluripotent cells. The sequence of the genes from mouse is set forth in **SEQ ID NO: 1** (GCR1 or Fragilis) and **SEQ ID NO: 3** (GCR2, or Stella). Corresponding amino acid sequences for mouse GCR1 and GCR2 are set out in **SEQ ID NO: 2** and **SEQ ID NO: 4** respectively. Nucleic acid sequences of rat GCR2 homologues are set out in **SEQ ID NO: 5**, **SEQ ID NO: 6**, **SEQ ID NO: 7**, **SEQ ID NO: 8**, and **SEQ ID NO: 9**.

According to a first aspect of the present invention, we provide a GCR1 polypeptide, or a fragment, homologue, variant or derivative thereof. Preferably, the polypeptide has at least 50%, 60%, 70%, 80%, 90% or 95% homology to a sequence shown in **SEQ ID NO: 2**.

There is provided, according to a second aspect of the present invention, GCR2 polypeptide, or a fragment, homologue, variant or derivative thereof. Preferably, the polypeptide has at least 50%, 60%, 70%, 80%, 90% or 95% homology to a sequence shown in **SEQ ID NO: 4**.

We provide, according to a third aspect of the present invention, a nucleic acid encoding a polypeptide according to any preceding claim.

As a fourth aspect of the present invention, there is provided a nucleic acid having at least 90% homology with the sequence set forth in SEQ ID NO: 1, or a
5 fragment, variant or derivative thereof.

We provide, according to a fifth aspect of the present invention, a nucleic acid having at least 75% homology with the sequence set forth in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, or a fragment, variant or derivative thereof

10 The present invention, in a sixth aspect, provides a nucleic acid comprising a sequence of 25 contiguous nucleotides of a nucleic acid according to the third, fourth or fifth aspect of the invention.

In a seventh aspect of the present invention, there is provided a nucleic acid comprising a sequence of 15 contiguous nucleotides of a nucleic acid according to
15 the third, fourth, fifth or sixth aspect of the invention.

According to an eighth aspect of the present invention, we provide a complement of a nucleic acid sequence according to any of the third to seventh aspect of the invention.

Preferably, such a nucleic acid comprises one or more nucleotide
20 substitutions, wherein such substitutions do not alter the coding specificity of said nucleic acid as a result of the degeneracy of the genetic code.

We provide, according to a ninth aspect of the invention, a polypeptide encoded by a nucleic acid according to any preceding aspect of the invention.

Preferably, the polypeptide comprises a sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4.

There is provided, in accordance with a tenth aspect of the present invention, a method for identifying a pluripotent cell, comprising detecting the presence of a polypeptide according to the first, second, ninth or tenth aspect of the invention or the expression of a nucleic acid according to any of the third to eighth aspect of the invention, or a homologue thereof.

Preferably, the method comprises the steps of amplifying nucleic acids from a putative pluripotent cell using 5' and 3' primers specific for GCR1 (Fragilis) and/or GCR2 (Stella), and detecting amplified nucleic acid thus produced. Preferably, the expression of the nucleic acid sequence is detected by *in situ* hybridisation.

The expression of the nucleic acid sequence may be determined by detecting the protein product encoded thereby. Alternatively or in addition, the protein product may be detected by immunostaining.

As an eleventh aspect of the invention, we provide an antibody specific for a polypeptide according to the first, second, ninth or tenth aspect of the invention. preferably, the antibody is capable of specifically binding to an extracellular domain of GCR1.

We provide, according to a twelfth aspect of the invention, there is provided use of such an antibody for the identification and/ or isolation of a pluripotent cell.

We further provide, according to a thirteenth aspect of the invention, a pluripotent cell identified by a method as set out previously.

There is provided, according to a fourteenth aspect of the present invention, a method for isolating a gene specifically expressed in a pluripotent cell, comprising

the steps of: (a) providing a population of cells containing a pluripotent cell; (b) isolating one or more pluripotent cells therefrom and providing single-cell pluripotent cell isolates; (c) amplifying the transcribed nucleic acid present in a single pluripotent cell; (d) conducting a subtractive hybridisation screen to identify
 5 transcripts present in pluripotent cells but not in somatic cells; and (e) probing a nucleic acid library with one or more transcripts identified in (d) to clone one or more genes which are specifically expressed in pluripotent cells.

In a highly preferred embodiment, the pluripotent cell is selected from the group consisting of: a primordial germ cell (PGC), an embryonic stem cell (ES) and
 10 an embryonic germ cell (EG). Preferably, the pluripotent cell comprises a primordial germ cell.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Nucleotide and deduced amino acid sequence of Fragilis. Predicted positions of the two transmembrane domains (TM I and TM II) are underlined and
 15 indicated by bold letters. The poly(A) signal is underlined.

Figure 2: Nucleotide and deduced amino acid sequence of Stella. Three nuclear localization signals are underlined. A potential nuclear export signal is underlined twice, and the hydrophobic residues are indicated in bold. Helical structures in a motif with similarity to SAP domain (a.a.28 to a.a.63) are underlined
 20 in red, and the conserved residues are indicated by blue. A splicing factor-like motif is underlined and the conserved residues are indicated in green. Poly(A) signals are also underlined.

Figure 3: Expression of Fragilis in embryonic stem (ES) cells. ES cells are fixed in 4% paraformaldehyde in PBS for 10min. at room temperature and processed
 25 for immunohistochemistry as described by Saitou et al., (1998). *J Cell Biol* 141, 397-408. (1998). Fragilis expression is similarly detected in E6.5 proximal epiblast cells, which are germ cell competent cells, and in newly specified germ cells. The

expression declines after E8.5 following completion of the specification of germ cells fate.

Figure 4: Expression of Stella in PGCs. PGCs from E12.5 genital ridges are fixed in 4% paraformaldehyde in PBS for 10min. at room temperature and processed for immunohistochemistry as described by Saitou et al., (1998). *J Cell Biol* 141, 397-408. (1998). Stella is detected in PGCs from E 7.25-13.5, as well as in pluripotent ES cells and in EG cells. Stella is also detected in the totipotent oocyte, zygote and in the totipotent and pluripotent blastomeres during preimplantation development and in developing gametes. When EG cells are derived from PGCs (Labosky *et al.*, (1994) *Development* 120:3197-3204). Fragilis expression is again detected in the pluripotent EG cells as it is in ES cells. Therefore, Fragilis and Stella are also markers for the pluripotent stem cells.

Figure 5. Fragilis expression by whole-mount *in situ* hybridization in E7.2 mouse embryos.

Figure 6. Stella expression by whole mount *in situ* hybridisation in E 7.2 mouse embryos.

Figure 7. Stella expression in PGCs in the process of migration into the gonads in E9.0 embryos.

Figure 8a and 8b. Expression of Fragilis and Stella in single cells detected by PCR analysis of single cell cDNAs. Numbers marked by symbol* in 8b are the PGCs. Note that there are more single cells showing expression of Fragilis compared to those showing expression of Stella. Only cells with the highest levels of Fragilis expression were found to express Stella and acquire the germ cell fate. Cells that express Stella were found not to show expression of Hoxb1. Cells that express lower levels of Fragilis and no Stella become somatic cells and showed expression of Hoxb1. The founder population of PGCs also show high levels of Tnap. Both the

founder PGCs and the somatic cells show expression of Oct4, T(Brachyury), and Fgf8.

Figure 9. The Fragilis family cluster on mouse Chr7, and the human homologues in the syntenic region on Chr11. In the mouse, the five Fragilis genes are clustered within a 70kb region. All genes are encoded by two exons, and apart from *fragilis2*, they are located on the minus strand. In human, the four homologous genes, *ENSG142056* and *Ifitm1* (9-27), *Ifitm2* (1-8D) and *Ifitm3* (1-8U), are clustered within a 25kb stretch. The four human homologues are each encoded by two exons, but the length of the intronic sequence for *Ifitm1* and *Ifitm3* is not known. Apart *Ifitm2*, all human genes are encoded on the minus strand. The green circles represent ISRE consensus sequences.

Figure 10. Protein alignment of the Fragilis family and their homologues in human, cow and rat. Green bars indicate the location of the two predicted transmembrane domains, of which the first as well as the inter-domain stretch appear to be highly conserved throughout the four mammalian species. Identical amino acids are highlighted in dark grey, similar amino acids in light grey. The alignment was done using ClustlW.

Figure 11. Expression analysis of *fragilis* (a-f), *fragilis2* (g-l) and *fragilis3* (m-r) by whole mount in situ hybridisation. Pictures are taken as lateral view unless otherwise stated, with anterior to the left and posterior to the right. *fragilis* is expressed throughout the epiblast in E5.5 embryos (a) and in the region of germ cell specification at the base of the incipient and early allantoic bud at E7.5 (b, b' posterior view, c). At E8.5, signal is detected at the base and in the proximal third of the allantois as well as in the latero-anterior aspects of the brain (d superior view, e anterior view). At E9.5, *fragilis* appears expressed in a population of cells at the beginning of the invaginating hindgut (arrow in f), as well as in the pharyngeal arches (f). *fragilis2* is detected throughout the epiblast at E5.5 (g). Expression seems thereafter downregulated but becomes again detectable in the posterior mesoderm and at the base of the incipient and growing allantoic bud in E7.0 and E7.5 embryos

(h, i, i' posterior view). At E8.5, expression is seen in caudal mesoderm (j, k posterior view), while at E9.5 expression is seen in the tailbud, the mesoderm caudal to the 12th somite and the lung primordia (arrow, l). *fragilis3* is expressed throughout the epiblast at E6.5 (m) and around E7.5 additionally in the region of PGC specification (n, n' posterior view, o). At E8.5, *fragilis2* expression is seen throughout the embryo, with exception of the developing heart, and appears intense in single cells (arrow in q posterior view) at the base and within the proximal region of the allantois (p posterior view, q, r). asterix: allantois; black arrowhead: allantoic bud; white arrowhead: developing heart; scale bars: 100µm (a, b, g-i, m, n); 200µm (c-e, o-q); 400µm (f, j-l, r).

Figure 12. Expression analysis of *fragilis2* by in situ hybridisation on sections. (a-d) transverse sections through the caudal region of an embryo at E9.5 (approx. 25 somites) at progressively rostral levels. At most caudal levels, *fragilis2* expression is seen in cells of the neural tube, in the presomitic mesoderm, in single cells within the hindgut (arrowhead) and in the body wall. (b) staining at approx. 23rd somite level is present within the forming somite, the body wall mesoderm and cells within the hindgut as well as the floorplate. (c) at approx. 21st somite level, expression in the differentiating somites is reduced, while cells in the floor plate and within the hindgut remain *fragilis2* mRNA positive. (d) at approx. the 13th somite level, *fragilis2* expression is absent from the somatic mesoderm as well as the neural tube. (e) sagittal section through an E10.5 embryo shows *fragilis2* expression in developing lung tissue (asterix; higher magnification in f) and migrating cells along the hindgut anterior to the dorsal aorta (arrow). (g) shows a magnified view of *fragilis2* mRNA expressing, migrating cells. da: dorsal aorta; fp: floor plate; g: gut; h: developing heart; nt: neural tube; s: somite; bw: body wall; scale bars: 150 µm (a-d); 1 mm (e); 400 µm (f, g).

Figure 13. Expression analysis of the Fragilis family genes in single cells from the region of germ cell specification of E7.5 embryos. (a) shows PCR analysis of cDNAs from three nascent, *stella* positive PGCs and three surrounding, *stella* negative somatic cells. Note that *fragilis*, *fragilis2* and *fragilis3* are expressed in

PGCs and somatic cells, while *fragilis4* and *fragilis5* are not detected in any of the cells. (b) shows expression of *fragilis*, *fragilis2* and *fragilis3* in single cell cDNAs using Southernblot analysis. GAPDH was used as blotting control. (c) Semi-quantitative expression analysis of the Southernblot data shows that all three *Fragilis* genes are predominantly expressed in nascent PGCs compared to the somatic cells within the region.

Figure 14. Expression analysis of *fragilis*, *fragilis2* and *fragilis3* at E11.5/E12.5 in single cells from the genital ridge and by in situ hybridisation. (a) shows PCR analysis of cDNAs from three gonadal *stella*-positive germ cells and three surrounding, *stella*-negative somatic cells. While *fragilis* is detected only in the three germ cell clones, *fragilis2* and *fragilis3* are expressed in the germ cells as well as the somatic cells. (b) shows in situ hybridisation of urogenital ridges of E11.5/E12.5 embryos. While *fragilis3* is expressed in the mesonephros as well as the genital ridge, *fragilis* and *fragilis2* are restricted to the genital ridge. The staining pattern for *fragilis* appears punctuate and restricted to single cells mimicking the pattern seen for the germ cell-specific *stella* gene. asterix: genital ridge; black arrowhead: mesonephros; scale bars: 400µm.

Figure 15. *Stella* expression during preimplantation development and evolutionary conservation. **a-l**, Confocal sections of anti-*stella* (**a,d,g,j**) and propidium iodide (**b,e,h,k**) stained embryos (**c,f,i,l** merged images). Maternal *stella* is stored in the unfertilised egg (**a-c**) (arrow, exclusion of *Stella* from condensed metaphase chromosomes) and localizes both to the cytoplasm and pronuclei (PN) after fertilisation (**d-f**; PB, polar body). Also during later stages (2-cell, **g-i**; 4-cell, **j-l**) it can be seen both in the cytoplasm and the nucleus. Scale bar = 20 µm. Synteny (**m**) of the *stella* gene in mouse, rat and human and close up view (**n**) of *stella* and its neighbouring genes in mouse and human. Arrows indicate the direction of transcription. **o**, Alignment of *Stella* protein sequences. Identical amino acids have a black background and similar amino acids a grey one. Putative nuclear export and localisation signals are marked by red and black lines, respectively. The red stars indicate conserved hydrophobic amino acids, which are typical for nuclear export

signals²⁷. **p**, RT-PCR analysis of *STELLA*-expression in human pluripotent cells and reproductive organs. *RPL32* was used as control. ES, embryonic stem cells; EC, embryonic carcinoma cells (nTera2); tet, testis tumor; te, normal testis; ov, normal ovary; -Rt, without reverse transcriptase; 0, water control.

5 Figure 16. Knockout strategy of *stella* and confirmation of correct targeting by Southern-blot and RT-PCR. **a**, The targeting vector was designed to delete exon 2 and replace it with an IRES-LacZ / MC-neo reporter-selection cassette. HSV-TK was used for negative selection against non-homologous recombination. 5', 3' and neo-probes were used to confirm correct targeting of ES-cells. **b**, Southern blot
10 analysis of genomic DNA derived from littermate mice born from a *stella*^{+/-} intercross. The example shows a NcoI digest hybridised with the 3' probe, indicating the absence of the wild-type allele in *stella*^{-/-} mice. **c**, RT-PCR of testis (te) or ovary (ov) RNA from male or female mice, respectively using exon 2-specific primers. The wild-type *stella* transcript is reduced in *stella*^{+/-} mice compared to *stella*^{+/+} mice
15 and absent in *stella*^{-/-} mice. *Gapdh* was used as a control for equivalent quality and amount of RNA. -Rt, without reverse transcriptase; 0, water control.

 Figure 17. Germ cell development in *stella* knockout mice. **a**, Numbers of PGCs in wild-type (wt, n=9), *stella*^{+/-} (n=14) and *stella*^{-/-} (n=7) embryos are not significantly different at E8.5 (0-8 somites). The results are presented as means
20 ±SEM. **b-g**, Gonadal PGCs (E11.5) stained with anti-stella (**b**, **e**) and anti-SSEA1 (**c**, **f**) antibodies (**d**, **g** merge including Toto3 (blue) as DNA stain). The PGC-marker SSEA1¹⁷ is coexpressed with stella in wild-type PGCs (**b-d**) and also detectable in *stella*^{-/-} animals (**e-g**), showing that PGCs are present in knockout mice. Scale bar = 10 µm. Sections of testes (**h-j**) and ovaries (**k-m**) of adult wild-type (**h**, **k**), *stella*^{+/-} (**i**,
25 **l**) and *stella*^{-/-} (**j**, **m**) mice. Knockout males show normal development of sperm (arrowheads) and knockout females normal ovary morphology with follicles containing oocytes of different stages (arrows). Scale bars in **j** (for **h-j**), **m** (for **k-m**) = 100 µm.

Figure 18. Maternal effect of the *stella* knockout and onset of paternal expression of *stella* during preimplantation development. **a**, 80% of matings with wild-type males resulted in pregnancies of wild-type females, while in only 24% of the plugs *stella*^{-/-} females became pregnant. **b**, From these pregnancies, the litter size was strongly reduced in knockouts compared to wild-type females. **c-i**, A *stella*-GFP reporter construct (**c**) was used to determine, when the paternal allele of *stella* starts to be expressed. Zygotic expression of the *stella*-GFP transgene begins at the 2-cell stage (E1.5; **e**, **h**) and continues during later stages (E2.5, 4-8 cell; **f**, **i**). **d-f**, GFP-fluorescence; **g-i**, brightfield merged with GFP-image; arrowheads, non-transgenic embryos; arrows, transgenic embryos. Scale bar in **d** (for **d-i**) = 100 μ m. **j-l**, Confocal section through a morula (E3.5) derived from a mating of a wild-type male with a *stella*^{-/-} female stained with anti-stella antibody (**j**) and propidium iodide (**k**) (**l**, merge). Stella protein is made from the paternal allele, but not sufficient to rescue the observed phenotype. Scale bar in **l** (for **j-l**) = 20 μ m

Figure 19. Preimplantation development is perturbed without Stella. **a**, The percentage of embryos developing *in vivo* to the various stages are given for *stella*^{-/-} (white bars) and wild-type or *stella*^{+/-} (black bars) mothers, respectively. Total numbers of embryos examined at each timepoint are given in parentheses. Development of knockout-derived embryos starts to be affected from E1.5 onwards (2-cell stage) and only a low percentage reach the blastocyst stage by E3.5 (**b**) compared to wild-type-derived embryos (**c**). **d-f**, Distribution of stages of embryos cultured *in vitro* from E1.5 until E4.5 (timepoint of implantation). Similar as *in vivo*, most embryos from wild-type mothers (black bars) develop to blastocysts (**f**), while many embryos of *stella* knockout mothers (white bars) are delayed or show abnormal morphology (**e**). Total number of embryos examined in **d**: -/- mothers: 41, wt or +/-mothers: 36. Scale bar = 100 μ m.

DETAILED DESCRIPTION

GCR1 (FRAGILIS) AND GCR2 (STELLA)

The disclosure provides generally for GCR1 (Fragilis) and GCR2 (Stella) nucleic acids, polypeptides, as well as fragments, homologues, variants and
 5 derivatives thereof.

The names “GCR1” and “Fragilis” should be understood as synonymous with each other, and likewise, “GCR2” and “Stella” should be considered synonyms. Nucleic acid and amino acid sequences of GCR1/Fragilis are set out in SEQ ID NO: 1 and 2, while nucleic acid sequences of GCR2/Stella are set out in SEQ ID NO: 3,
 10 5, 6, 7, 8 and 9, with an amino acid sequence of GCR2/Stella shown in SEQ ID NO: 4.

In preferred embodiments, however, GCR1/ Fragilis should be taken to refer to the nucleic acid sequence shown in SEQ ID NO: 1, or the amino acid sequence shown in SEQ ID NO: 2, as the context requires. Furthermore, in preferred
 15 embodiments, GCR2/ Stella should be taken to refer to the nucleic acid sequence shown in SEQ ID NO: 3, or the amino acid sequence shown in SEQ ID NO: 4, as the context requires.

GCR1 and GCR2 are PGC-specific transcripts. GCR1 is upregulated during the process of lineage commitment of PGCs, while GCR2 is upregulated after
 20 GCR1, and marks commitment to the PGC fate. The first gene, GCR1 (Germ cell restricted-1, Fragilis), encodes a 137 amino acid protein with a predicted molecular weight of 15.0kD. The best fit model of the EMBL program PredictProtein predicts two transmembrane domains, both N and C terminus ends being located outside. The BLASTP search revealed that Fragilis is a novel member of the interferon-
 25 inducible protein family. One prototype member, human 9-27 (identical to Leu-13 antigen), is inducible by interferon in leukocytes and endothelial cells, and is located at the cell surface as a component of a multimeric complex involved in the

transduction of antiproliferative and homotypic adhesion signals (Deblandre, 1995). The BLASTN search revealed that the Fragilis sequence was found in ESTs derived from many different tissues both from embryos and adults, indicating that Fragilis may play a common role in different developmental and cell biological contexts.

- 5 Database searches reveal a sequence match with the rat interferon-inducible protein (sp:INIB RAT, pir:JC1241) with unknown function. The GCR1 sequence appears six times in our screen, indicating high level expression in PGCs.

- The second gene, GCR2, (Stella) encodes a 150 amino acid protein, of 18kD. It has no sequence homology with any known protein, contains several nuclear localisation consensus sequences and is highly basic pI (pI=9.67, the content of basic residues=23.3%), indicating a possible affinity to DNA. Furthermore a potential nuclear export signal was identified, indicating that Stella may shuttle between the nucleus and the cytoplasm. BLASTN analysis revealed that the Stella sequence was found only in the preimplantation embryo and germ line (newborn ovary, female 12.5 mesonephros and gonad etc.) ESTs indicating its predominant expression in totipotent and pluripotent cells. Interestingly, we found that Stella contains in its N terminus a modular domain which has some sequence similarity with the SAP motif. This motif is a putative DNA-binding domain involved in chromosomal organisation. Furthermore, the SMART program revealed the presence of a splicing factor motif-like structure in its C-terminus, These findings indicate a possible involvement of Stella in chromosomal organisation and RNA processing.

- Antibodies may be raised against the GCR1 and/or GCR2 polypeptides. In particular, antibodies may be raised against the extracellular domain of GCR1, which is a transmembrane polypeptide.

Antibodies and nucleic acids disclosed here are useful for the identification of PGCs in cell populations. The methods and compositions described here therefore provide a means to isolate PGCs, useful for example for the study of germ tissue

development and the generation of transgenic animals, and PGCs when isolated by a method described here.

Homologues of GCR1 and GCR2 may also be used to identify PGCs and other pluripotent cells, such as ES or EG cells.

5 The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A*
 10 *Laboratory Manual*, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements; *Current Protocols in Molecular Biology*, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, *DNA Isolation and Sequencing: Essential*
Techniques, John Wiley & Sons; J. M. Polak and James O'D. McGee, 1990, *In Situ*
 15 *Hybridization: Principles and Practice*; Oxford University Press; M. J. Gait (Editor), 1984, *Oligonucleotide Synthesis: A Practical Approach*, Irl Press; and, D. M. J. Lilley and J. E. Dahlberg, 1992, *Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA* Methods in Enzymology, Academic Press. Each of these general texts is herein incorporated by reference.

20 **POLYPEPTIDES**

 It will be understood that polypeptide sequences disclosed here are not limited to the particular sequences set forth in SEQ ID NO: 2 and SEQ ID NO: 4, or fragments thereof, or sequences obtained from GCR1 or GCR2 protein, but also include homologous sequences obtained from any source, for example related
 25 cellular homologues, homologues from other species and variants or derivatives thereof.

This disclosure therefore encompasses variants, homologues or derivatives of the amino acid sequences set forth in SEQ ID NO: 2 and SEQ ID NO: 4, as well as variants, homologues or derivatives of the amino acid sequences encoded by the nucleotide sequences disclosed here.

5 *Homologues*

The polypeptides disclosed include homologous sequences obtained from any source, for example related viral/bacterial proteins, cellular homologues and synthetic peptides, as well as variants or derivatives thereof. Thus polypeptides also include those encoding homologues of GCR1 and/or GCR2 from other species
10 including animals such as mammals (e.g. mice, rats or rabbits), especially primates, more especially humans. More specifically, homologues include human homologues.

In the context of the present document, a homologous sequence or homologue is taken to include an amino acid sequence which is at least 60, 70, 80 or
15 90% identical, preferably at least 95 or 98% identical at the amino acid level over at least 30, preferably 50, 70, 90 or 100 amino acids with GCR1 or GCR2, for example as shown in the sequence listing herein. In the context of this document, a homologous sequence is taken to include an amino acid sequence which is at least
20 15, 20, 25, 30, 40, 50, 60, 70, 80 or 90% identical, preferably at least 95 or 98% identical at the amino acid level, preferably over at least 50 or 100, preferably 200, 300, 400 or 500 amino acids with the sequence of GCR1 or GCR2, for example GCR1 (SEQ ID NO: 2) and GCR2 (SEQ ID NO: 4). Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present document it is preferred to
25 express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

% homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an “ungapped” alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues (for example less than 50 contiguous amino acids).

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting “gaps” in the sequence alignment to try to maximise local homology.

However, these more complex methods assign “gap penalties” to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. “Affine gap costs” are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package (see below) the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package

(University of Wisconsin, U.S.A.; Devereux *et al.*, 1984, Nucleic Acids Research 12:387). Examples of other software than can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel *et al.*, 1999 *ibid* – Chapter 18), FASTA (Atschul *et al.*, 1990, J. Mol. Biol., 403-410) and the GENWORKS
 5 suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel *et al.*, 1999 *ibid*, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program.

Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison.
 10 Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see
 15 user manual for further details). It is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does
 20 this as part of the sequence comparison and generates a numerical result.

Variants and Derivatives

The terms “variant” or “derivative” in relation to the amino acid sequences as described here includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the
 25 sequence. Preferably, the resultant amino acid sequence retains substantially the same activity as the unmodified sequence, preferably having at least the same activity as the GCR1 and/or GCR2 polypeptides shown in the sequence listings. Thus, the key feature of the sequences – namely that they are specific for PGCs and

other pluripotent cells, such as ES or EG cells, and can serve as a marker for these cells in a cell population – is preferably retained.

Polypeptides having the amino acid sequence shown in the Examples, or fragments or homologues thereof may be modified for use in the methods and compositions described here. Typically, modifications are made that maintain the biological activity of the sequence. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions provided that the modified sequence retains the biological activity of the unmodified sequence. Amino acid substitutions may include the use of non-naturally occurring analogues, for example to increase blood plasma half-life of a therapeutically administered polypeptide.

Natural variants of GCR1 and GCR2 are likely to comprise conservative amino acid substitutions. Conservative substitutions may be defined, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

Fragments

Polypeptides disclosed here and useful as markers also include fragments of the above mentioned full length polypeptides and variants thereof, including fragments of the sequences set out in SEQ ID NO:2 and SEQ ID NO: 4.

Polypeptides also include fragments of the full length sequence of any of the GCR1 and/or GCR2 polypeptides. Preferably fragments comprise at least one epitope. Methods of identifying epitopes are well known in the art. Fragments will typically comprise at least 6 amino acids, more preferably at least 10, 20, 30, 50 or
 5 100 amino acids.

Included are fragments comprising, preferably consisting of, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76,
 10 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145 or 150, or more residues from a GCR1 and/or GCR2 amino acid sequence.

Polypeptide fragments of the GCR proteins and allelic and species variants thereof may contain one or more (e.g. 5, 10, 15, or 20) substitutions, deletions or
 15 insertions, including conserved substitutions. Where substitutions, deletion and/or insertions occur, for example in different species, preferably less than 50%, 40% or 20% of the amino acid residues depicted in the sequence listings are altered.

GCR1 and/ GCR2, and their fragments, homologues, variants and derivatives, may be made by recombinant means. However, they may also be made
 20 by synthetic means using techniques well known to skilled persons such as solid phase synthesis. The proteins may also be produced as fusion proteins, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β -galactosidase. It may also be convenient to include a
 25 proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the function of the protein of interest sequence. Proteins may also be obtained by purification of cell extracts from animal cells.

The GCR1 and/or GCR2 polypeptides, variants, homologues, fragments and derivatives disclosed here may be in a substantially isolated form. It will be understood that such polypeptides may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A GCR1/GCR2 variant, homologue, fragment or derivative may also be in a substantially purified form, in which case it will generally comprise the protein in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the protein in the preparation is a protein.

The GCR1/GCR2 polypeptides, variants, homologues, fragments and derivatives disclosed here may be labelled with a revealing label. The revealing label may be any suitable label which allows the polypeptide, etc to be detected. Suitable labels include radioisotopes, e.g. ^{125}I , enzymes, antibodies, polynucleotides and linkers such as biotin. Labelled polypeptides may be used in diagnostic procedures such as immunoassays to determine the amount of a polypeptide in a sample. Polypeptides or labelled polypeptides may also be used in serological or cell-mediated immune assays for the detection of immune reactivity to said polypeptides in animals and humans using standard protocols.

GCR1/GCR2 polypeptides, variants, homologues, fragments and derivatives disclosed here, optionally labelled, may also be fixed to a solid phase, for example the surface of an immunoassay well or dipstick. Such labelled and/or immobilised polypeptides may be packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like. Such polypeptides and kits may be used in methods of detection of antibodies to the polypeptides or their allelic or species variants by immunoassay.

Immunoassay methods are well known in the art and will generally comprise: (a) providing a polypeptide comprising an epitope bindable by an antibody against said protein; (b) incubating a biological sample with said polypeptide under conditions which allow for the formation of an antibody-antigen

complex; and (c) determining whether antibody-antigen complex comprising said polypeptide is formed.

The GCR1/GCR2 polypeptides, variants, homologues, fragments and derivatives disclosed here may be used in *in vitro* or *in vivo* cell culture systems to study the role of their corresponding genes and homologues thereof in cell function, including their function in disease. For example, truncated or modified polypeptides may be introduced into a cell to disrupt the normal functions which occur in the cell. The polypeptides may be introduced into the cell by *in situ* expression of the polypeptide from a recombinant expression vector (see below). The expression vector optionally carries an inducible promoter to control the expression of the polypeptide.

The use of appropriate host cells, such as insect cells or mammalian cells, is expected to provide for such post-translational modifications (e.g. myristolation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products. Such cell culture systems in which the GCR1/GCR2 polypeptides, variants, homologues, fragments and derivatives disclosed here are expressed may be used in assay systems to identify candidate substances which interfere with or enhance the functions of the polypeptides in the cell.

GCR1/GCR2 NUCLEIC ACIDS

The methods and compositions described here provide generally for a number of GCR1 and GCR2 nucleic acids, together with fragments, homologues, variants and derivatives thereof. These nucleic acid sequences preferably encode the polypeptide sequences disclosed here, and particularly in the sequence listings. Preferably, the polynucleotides comprise *Stella* and/or *Fragilis* nucleic acids, preferably selected from the group consisting of: SEQ ID NO: 1, 3, 5, 6, 7, 8 or 9, fragments, homologues, variants and derivatives thereof.

In particular, we provide for nucleic acids which encode any of the GCR1 and/or GCR2 polypeptides disclosed here. Thus, the terms “GCR nucleic acid”, “GCR1 nucleic acid” and “GCR2 nucleic acid” should be construed accordingly. Preferably, however, such nucleic acids comprise any of the sequences set out as
5 SEQ ID NO: 1, 3, 5, 6, 7, 8 or 9 or a sequence encoding any of the polypeptides SEQ ID NO: 2 and 4, and a fragment, homologue, variant or derivative of such a nucleic acid. The above terms therefore preferably should be taken to refer to these sequences.

As used here in this document, the terms “polynucleotide”, “nucleotide”, and
10 nucleic acid are intended to be synonymous with each other. “Polynucleotide” generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA
15 that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified
20 bases and DNAs or RNAs with backbones modified for stability or for other reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms
25 of DNA and RNA characteristic of viruses and cells. “Polynucleotide” also embraces relatively short polynucleotides, often referred to as oligonucleotides.

It will be understood by a skilled person that numerous different polynucleotides and nucleic acids can encode the same polypeptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled
30 persons may, using routine techniques, make nucleotide substitutions that do not

affect the polypeptide sequence encoded by the polynucleotides described here to reflect the codon usage of any particular host organism in which the polypeptides are to be expressed.

5 *Variants, Derivatives and Homologues*

The polynucleotides described here may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include

10 methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present document, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of polynucleotides.

15 Where the polynucleotide is double-stranded, both strands of the duplex, either individually or in combination, are encompassed by the methods and compositions described here. Where the polynucleotide is single-stranded, it is to be understood that the complementary sequence of that polynucleotide is also included.

20 The terms “variant”, “homologue” or “derivative” in relation to a nucleotide sequence include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleotides from or to the sequence providing the resultant nucleotide sequence is specific for pluripotent cells, preferably specific for PGCs, ES cells or EG cells. Most preferably, the resultant nucleotide sequence is specific for PGCs.

25 As indicated above, with respect to sequence identity, a “homologue” has preferably at least 5% identity, at least 10% identity, at least 15% identity, at least

20% identity, at least 25% identity, at least 30% identity, at least 35% identity, at least 40% identity, at least 45% identity, at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, or at least
 5 95% identity to the relevant sequence shown in the sequence listings.

More preferably there is at least 95% identity, more preferably at least 96% identity, more preferably at least 97% identity, more preferably at least 98% identity, more preferably at least 99% identity. Nucleotide homology comparisons may be conducted as described above. A preferred sequence comparison program is
 10 the GCG Wisconsin Bestfit program described above. The default scoring matrix has a match value of 10 for each identical nucleotide and -9 for each mismatch. The default gap creation penalty is -50 and the default gap extension penalty is -3 for each nucleotide.

Hybridisation

15 We further describe nucleotide sequences that are capable of hybridising selectively to any of the sequences presented herein, or any variant, fragment or derivative thereof, or to the complement of any of the above. Nucleotide sequences are preferably at least 15 nucleotides in length, more preferably at least 20, 30, 40 or 50 nucleotides in length.

20 The term “hybridisation” as used herein shall include “the process by which a strand of nucleic acid joins with a complementary strand through base pairing” as well as the process of amplification as carried out in polymerase chain reaction technologies.

Polynucleotides capable of selectively hybridising to the nucleotide sequences
 25 presented herein, or to their complement, will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% or 98% homologous to the corresponding nucleotide sequences presented herein over a region of at least 20,

preferably at least 25 or 30, for instance at least 40, 60 or 100 or more contiguous nucleotides.

The term “selectively hybridisable” means that the polynucleotide used as a probe is used under conditions where a target polynucleotide is found to hybridize to the probe at a level significantly above background. The background hybridization may occur because of other polynucleotides present, for example, in the cDNA or genomic DNA library being screening. In this event, background implies a level of signal generated by interaction between the probe and a non-specific DNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target DNA. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ^{32}P .

Hybridisation conditions are based on the melting temperature (T_m) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA), and confer a defined “stringency” as explained below.

Maximum stringency typically occurs at about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe); high stringency at about 5°C to 10°C below T_m ; intermediate stringency at about 10°C to 20°C below T_m ; and low stringency at about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a maximum stringency hybridisation can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridisation can be used to identify or detect similar or related polynucleotide sequences.

In a preferred aspect, we disclose nucleotide sequences that can hybridise to a GCR1/GCR2 nucleic acid, or a fragment, homologue, variant or derivative thereof, under stringent conditions (e.g. 65°C and $0.1\times\text{SSC}$ { $1\times\text{SSC} = 0.15\text{ M NaCl}$, $0.015\text{ M Na}_3\text{ Citrate pH } 7.0$ }).

Where a polynucleotide is double-stranded, both strands of the duplex, either individually or in combination, are encompassed by the present disclosure. Where the polynucleotide is single-stranded, it is to be understood that the complementary sequence of that polynucleotide is also disclosed and encompassed.

5 Polynucleotides which are not 100% homologous to the sequences disclosed here but fall within the disclosure can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other viral/bacterial, or cellular homologues particularly
10 cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells, including human cells), may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing
15 such libraries with probes comprising all or part of SEQ ID NOs: 1 or 3 under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of GCR1 and GCR2.

The polynucleotides described here may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled
20 with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides as used herein. Preferred fragments are less than 500, 200, 100, 50 or 20 nucleotides in length.

25 Polynucleotides such as a DNA polynucleotides and probes may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

Longer polynucleotides will generally be produced using recombinant means,
 5 for example using PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region,
 10 isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector

NUCLEOTIDE VECTORS

15 The polynucleotides can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, we provide a method of making polynucleotides by introducing a polynucleotide into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about
 20 replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as *E. coli*, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.

Preferably, a polynucleotide in a vector is operably linked to a control sequence that is capable of providing for the expression of the coding sequence by
 25 the host cell, i.e. the vector is an expression vector. The term “operably linked” means that the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence “operably linked” to a

coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

The control sequences may be modified, for example by the addition of further transcriptional regulatory elements to make the level of transcription directed
5 by the control sequences more responsive to transcriptional modulators.

Vectors may be transformed or transfected into a suitable host cell as described below to provide for expression of a protein. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the
10 protein, and optionally recovering the expressed protein.

The vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in
15 the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used, for example, to transfect or transform a host cell.

Control sequences operably linked to sequences encoding the protein include promoters/enhancers and other expression regulation signals. These control sequences may be selected to be compatible with the host cell for which the
20 expression vector is designed to be used in. The term “promoter” is well-known in the art and encompasses nucleic acid regions ranging in size and complexity from minimal promoters to promoters including upstream elements and enhancers.

The promoter is typically selected from promoters which are functional in mammalian cells, although prokaryotic promoters and promoters functional in other
25 eukaryotic cells may be used. The promoter is typically derived from promoter sequences of viral or eukaryotic genes. For example, it may be a promoter derived from the genome of a cell in which expression is to occur. With respect to

eukaryotic promoters, they may be promoters that function in a ubiquitous manner (such as promoters of α -actin, β -actin, tubulin) or, alternatively, a tissue-specific manner (such as promoters of the genes for pyruvate kinase). They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR) promoter, the Rous sarcoma virus (RSV) LTR promoter or the human cytomegalovirus (CMV) IE promoter.

It may also be advantageous for the promoters to be inducible so that the levels of expression of the heterologous gene can be regulated during the life-time of the cell. Inducible means that the levels of expression obtained using the promoter can be regulated.

In addition, any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.

HOST CELLS

Vectors and polynucleotides disclosed here may be introduced into host cells for the purpose of replicating the vectors/polynucleotides and/or expressing the proteins. Although the proteins may be produced using prokaryotic cells as host cells, it is preferred to use eukaryotic cells, for example yeast, insect or mammalian cells, in particular mammalian cells.

Vectors/polynucleotides may be introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation and electroporation. Where vectors/polynucleotides as disclosed here are to be administered to animals, several techniques are known in the art, for example

infection with recombinant viral vectors such as retroviruses, herpes simplex viruses and adenoviruses, direct injection of nucleic acids and biolistic transformation.

PROTEIN EXPRESSION AND PURIFICATION

Host cells comprising polynucleotides disclosed here may be used to express
5 proteins. Host cells may be cultured under suitable conditions which allow
expression of the proteins. Expression of the proteins described here may be
constitutive such that they are continually produced, or inducible, requiring a
stimulus to initiate expression. In the case of inducible expression, protein
production can be initiated when required by, for example, addition of an inducer
10 substance to the culture medium, for example dexamethasone or IPTG.

Proteins can be extracted from host cells by a variety of techniques known in
the art, including enzymatic, chemical and/or osmotic lysis and physical disruption.

RECOMBINANT STELLA AND FRAGILIS PROTEINS

Nucleotide sequences of Stella and Fragilis are cloned into a TRI-system
15 vector (Qiagen). Stella sequence comprising the second codon onwards (i.e., an N
terminal fragment of Stella without the first ATG codon) is cloned into a pQE vector
using appropriate restriction enzyme sites, and according to the manufacturers
instructions. QIAexpress pQE vectors enable high-level expression of 6xHis-tagged
proteins in *E. coli*.

20 A His tag is placed in the N terminal portion of the Stella gene. Recombinant
protein is purified by affinity chromatography on a Ni-NTA column, according to
manufacturer's instructions. The His tag is cleaved using a suitable protease.

Recombinantly expressed Stella and Fragilis protein are found to be
biologically active.

TRANSGENIC ANIMALS

We further describe transgenic animals capable of expressing natural or recombinant Stella and/or Fragilis, or a homologue, variant or derivative, at elevated or reduced levels compared to the normal expression level. Included are transgenic animals (“Stella knockout”s or “Fragilis knockout”s) which do not express functional Stella and/or Fragilis, as the case may be. The Stella and Fragilis knockouts may arise as a result of functional disruption of the Stella and/or Fragilis gene or any portion of that gene, including one or more loss of function mutations, including a deletion or replacement, of the Stella and/or Fragilis gene. The mutations include single point mutations, and may target coding or non-coding regions of Stella and/or Fragilis.

Preferably, such a transgenic animal is a non-human mammal, such as a pig, a sheep or a rodent. Most preferably the transgenic animal is a mouse or a rat. Such transgenic animals may be used in screening procedures to identify agonists and/or antagonists of Stella and/or Fragilis, as well as to test for their efficacy as treatments for diseases *in vivo*.

Mice which are null for Stella and/or Fragilis may be used for various purposes. For example, transgenic animals that have been engineered to be deficient in the production of Stella and/or Fragilis may be used in assays to identify agonists and/or antagonists of Stella and/or Fragilis. One assay is designed to evaluate a potential drug (a candidate ligand or compound) to determine if it produces a physiological response in the absence Stella and/or Fragilis. This may be accomplished by administering the drug to a transgenic animal as discussed above, and then assaying the animal for a particular response.

Tissues derived from the Stella and/or Fragilis knockout animals may be used in binding assays to determine whether the potential drug (a candidate ligand or compound) binds to Stella or Fragilis, as the case may be. Such assays can be conducted by obtaining a first Stella and/or Fragilis preparation from the transgenic

animal engineered to be deficient in Stella and/or Fragilis production and a second Stella and/or Fragilis preparation from a source known to bind any identified ligands or compounds. In general, the first and second preparations will be similar in all respects except for the source from which they are obtained. For example, if brain
5 tissue from a transgenic animal (such as described above and below) is used in an assay, comparable brain tissue from a normal (wild type) animal is used as the source of the second preparation. Each of the preparations is incubated with a ligand known to bind to Stella and/or Fragilis, both alone and in the presence of the candidate ligand or compound. Preferably, the candidate ligand or compound will be
10 examined at several different concentrations.

The extent to which binding by the known ligand is displaced by the test compound is determined for both the first and second preparations. Tissues derived from transgenic animals may be used in assays directly or the tissues may be processed to isolate Stella and/or Fragilis proteins, which are themselves used in the
15 assays. A preferred transgenic animal is the mouse. The ligand may be labeled using any means compatible with binding assays. This would include, without limitation, radioactive, enzymatic, fluorescent or chemiluminescent labeling (as well as other labelling techniques as described in further detail above).

Furthermore, antagonists of Stella and/or Fragilis may be identified by
20 administering candidate compounds, etc, to wild type animals expressing functional Stella and/or Fragilis, and animals identified which exhibit any of the phenotypic characteristics associated with reduced or abolished expression of Stella and/or Fragilis function.

Methods for generating non-human transgenic animal are known in the art,
25 and are described in further detail in the Examples below. Transgenic gene constructs can be introduced into the germ line of an animal to make a transgenic mammal. For example, one or several copies of the construct may be incorporated into the genome of a mammalian embryo by standard transgenic techniques.

In an exemplary embodiment, the transgenic non-human animals described here are produced by introducing transgenes into the germline of the non-human animal. Embryonal target cells at various developmental stages can be used to introduce transgenes. Different methods are used depending on the stage of development of the embryonal target cell. The specific line(s) of any animal used to produce transgenic animals are selected for general good health, good embryo yields, good pronuclear visibility in the embryo, and good reproductive fitness. In addition, the haplotype is a significant factor.

Introduction of the transgene into the embryo can be accomplished by any means known in the art such as, for example, microinjection, electroporation, or lipofection. For example, the Stella or Fragilis transgene can be introduced into a mammal by microinjection of the construct into the pronuclei of the fertilized mammalian egg(s) to cause one or more copies of the construct to be retained in the cells of the developing mammal(s). Following introduction of the transgene construct into the fertilized egg, the egg may be incubated *in vitro* for varying amounts of time, or reimplanted into the surrogate host, or both. *In vitro* incubation to maturity is also included. One common method is to incubate the embryos *in vitro* for about 1-7 days, depending on the species, and then reimplant them into the surrogate host.

The progeny of the transgenically manipulated embryos can be tested for the presence of the construct by Southern blot analysis of the segment of tissue. If one or more copies of the exogenous cloned construct remains stably integrated into the genome of such transgenic embryos, it is possible to establish permanent transgenic mammal lines carrying the transgenically added construct.

The litters of transgenically altered mammals can be assayed after birth for the incorporation of the construct into the genome of the offspring. Preferably, this assay is accomplished by hybridizing a probe corresponding to the DNA sequence coding for the desired recombinant protein product or a segment thereof onto

chromosomal material from the progeny. Those mammalian progeny found to contain at least one copy of the construct in their genome are grown to maturity.

For the purposes of this document, a zygote is essentially the formation of a diploid cell which is capable of developing into a complete organism. Generally, the zygote will be comprised of an egg containing a nucleus formed, either naturally or artificially, by the fusion of two haploid nuclei from a gamete or gametes. Thus, the gamete nuclei must be ones which are naturally compatible, i.e., ones which result in a viable zygote capable of undergoing differentiation and developing into a functioning organism. Generally, a euploid zygote is preferred. If an aneuploid zygote is obtained, then the number of chromosomes should not vary by more than one with respect to the euploid number of the organism from which either gamete originated.

In addition to similar biological considerations, physical ones also govern the amount (e.g., volume) of exogenous genetic material which can be added to the nucleus of the zygote or to the genetic material which forms a part of the zygote nucleus. If no genetic material is removed, then the amount of exogenous genetic material which can be added is limited by the amount which will be absorbed without being physically disruptive. Generally, the volume of exogenous genetic material inserted will not exceed about 10 picoliters. The physical effects of addition must not be so great as to physically destroy the viability of the zygote. The biological limit of the number and variety of DNA sequences will vary depending upon the particular zygote and functions of the exogenous genetic material and will be readily apparent to one skilled in the art, because the genetic material, including the exogenous genetic material, of the resulting zygote must be biologically capable of initiating and maintaining the differentiation and development of the zygote into a functional organism.

The number of copies of the transgene constructs which are added to the zygote is dependent upon the total amount of exogenous genetic material added and will be the amount which enables the genetic transformation to occur. Theoretically

only one copy is required; however, generally, numerous copies are utilized, for example, 1,000-20,000 copies of the transgene construct, in order to insure that one copy is functional. There will often be an advantage to having more than one functioning copy of each of the inserted exogenous DNA sequences to enhance the phenotypic expression of the exogenous DNA sequences.

Any technique which allows for the addition of the exogenous genetic material into nucleic genetic material can be utilized so long as it is not destructive to the cell, nuclear membrane or other existing cellular or genetic structures. The exogenous genetic material is preferentially inserted into the nucleic genetic material by microinjection. Microinjection of cells and cellular structures is known and is used in the art.

Reimplantation is accomplished using standard methods. Usually, the surrogate host is anesthetized, and the embryos are inserted into the oviduct. The number of embryos implanted into a particular host will vary by species, but will usually be comparable to the number of off spring the species naturally produces.

Transgenic offspring of the surrogate host may be screened for the presence and/or expression of the transgene by any suitable method. Screening is often accomplished by Southern blot or Northern blot analysis, using a probe that is complementary to at least a portion of the transgene. Western blot analysis using an antibody against the protein encoded by the transgene may be employed as an alternative or additional method for screening for the presence of the transgene product. Typically, DNA is prepared from tail tissue and analyzed by Southern analysis or PCR for the transgene. Alternatively, the tissues or cells believed to express the transgene at the highest levels are tested for the presence and expression of the transgene using Southern analysis or PCR, although any tissues or cell types may be used for this analysis.

Alternative or additional methods for evaluating the presence of the transgene include, without limitation, suitable biochemical assays such as enzyme

and/or immunological assays, histological stains for particular marker or enzyme activities, flow cytometric analysis, and the like. Analysis of the blood may also be useful to detect the presence of the transgene product in the blood, as well as to evaluate the effect of the transgene on the levels of various types of blood cells and other blood constituents.

Progeny of the transgenic animals may be obtained by mating the transgenic animal with a suitable partner, or by in vitro fertilization of eggs and/or sperm obtained from the transgenic animal. Where mating with a partner is to be performed, the partner may or may not be transgenic and/or a knockout; where it is transgenic, it may contain the same or a different transgene, or both. Alternatively, the partner may be a parental line. Where in vitro fertilization is used, the fertilized embryo may be implanted into a surrogate host or incubated in vitro, or both. Using either method, the progeny may be evaluated for the presence of the transgene using methods described above, or other appropriate methods.

The transgenic animals produced in accordance the methods described here will include exogenous genetic material. As set out above, the exogenous genetic material will, in certain embodiments, be a DNA sequence which results in the production of a Stella and/or Fragilis protein. Further, in such embodiments the sequence will be attached to a transcriptional control element, e.g., a promoter, which preferably allows the expression of the transgene product in a specific type of cell.

It will be appreciated that it is possible to manipulate the control elements (promoters or enhancers) to regulate the spatial or temporal expression, or both, of Stella or Fragilis (as the case may be). For example, specific control elements may be deleted from the endogenous Stella and/or Fragilis locus so that expression is restricted to only certain tissues. Alternatively, it is possible to prepare transgenes which only contain one, some, or more, of the control elements. Transgenic animals made this way for Stella and/or Fragilis and having properties of ectopic expression,

temporally or spatially, or both, will be useful for investigation of Stella and/or Fragilis gene function.

Retroviral infection can also be used to introduce transgene into a non-human animal. The developing non-human embryo can be cultured in vitro to the blastocyst stage. During this time, the blastomeres can be targets for retroviral infection (Jaenich, R. (1976) PNAS 73:1260-1264). Efficient infection of the blastomeres is obtained by enzymatic treatment to remove the zona pellucida (Manipulating the Mouse Embryo, Hogan eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1986). The viral vector system used to introduce the transgene is typically a replication-defective retrovirus carrying the transgene (Jahner et al. (1985) PNAS 82:6927-6931; Van der Putten et al. (1985) PNAS 82:6148-6152). Transfection is easily and efficiently obtained by culturing the blastomeres on a monolayer of virus-producing cells (Van der Putten, supra; Stewart et al. (1987) EMBO J. 6:383-388). Alternatively, infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele (Jahner et al. (1982) Nature 298:623-628). Most of the founders will be mosaic for the transgene since incorporation occurs only in a subset of the cells which formed the transgenic non-human animal. Further, the founder may contain various retroviral insertions of the transgene at different positions in the genome which generally will segregate in the offspring. In addition, it is also possible to introduce transgenes into the germ line by intrauterine retroviral infection of the midgestation embryo (Jahner et al. (1982) supra).

A third type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells are obtained from pre-implantation embryos cultured in vitro and fused with embryos (Evans et al. (1981) Nature 292:154-156; Bradley et al. (1984) Nature 309:255-258; Gossler et al. (1986) PNAS 83: 9065-9069; and Robertson et al. (1986) Nature 322:445-448). Transgenes can be efficiently introduced into the ES cells by DNA transfection or by retrovirus-mediated transduction. Such transformed ES cells can thereafter be combined with blastocysts from a non-human animal. The ES cells thereafter colonize the embryo and contribute to the germ line

of the resulting chimeric animal. For review see Jaenisch, R. (1988) Science 240:1468-1474.

We also provide non-human transgenic animals, where the transgenic animal is characterized by having an altered Stella and/or Fragilis gene, preferably as described above, as models for Stella or Fragilis function, as the case may be. Alterations to the gene include deletions or other loss of function mutations, introduction of an exogenous gene having a nucleotide sequence with targeted or random mutations, introduction of an exogenous gene from another species, or a combination thereof. The transgenic animals may be either homozygous or heterozygous for the alteration. The animals and cells derived therefrom are useful for screening biologically active agents that may modulate Stella and/or Fragilis function. The screening methods are of particular use for determining the specificity and action of potential therapies for Stella and/or Fragilis associated diseases, as described above. The animals are useful as a model to investigate the role of Stella and/or Fragilis proteins in the body.

Another aspect pertains to a transgenic animal having a functionally disrupted endogenous Stella or Fragilis gene, or both, but which also carries in its genome, and expresses, a transgene encoding a heterologous Stella and/or Fragilis protein (i.e., a Stella and/or Fragilis gene from another species). Preferably, the animal is a mouse and the heterologous Stella or Fragilis is a human Stella or Fragilis. An animal, or cell lines derived from such an animal, which has been reconstituted with human Stella and/or Fragilis, can be used to identify agents that inhibit human Stella and/or Fragilis *in vivo* and *in vitro*. For example, a stimulus that induces signalling through human Stella and/or Fragilis can be administered to the animal, or cell line, in the presence and absence of an agent to be tested and the response in the animal, or cell line, can be measured. An agent that inhibits human Stella and/or Fragilis *in vivo* or *in vitro* can be identified based upon a decreased response in the presence of the agent compared to the response in the absence of the agent.

We also provide for a Stella and/or Fragilis deficient transgenic non-human animal (a “Stella/Fragilis knock-out” or a “Stella/Fragilis null”). Such an animal is one which expresses lowered or no Stella/Fragilis activity, preferably as a result of an endogenous Stella or Fragilis (as the case may be) genomic sequence being
5 disrupted or deleted. The endogenous Stella or Fragilis genomic sequence may be replaced by a null allele, which may comprise non-functional portions of the wild-type Stella/Fragilis sequence. For example, the endogenous Stella/Fragilis genomic sequence may be replaced by an allele of Stella/Fragilis comprising a disrupting sequence which may comprise heterologous sequences, for example, reporter
10 sequences and/or selectable markers. Preferably, the endogenous Stella/Fragilis genomic sequence in a Stella/Fragilis knock-out mouse is replaced by an allele of Stella or Fragilis in which one or more, preferably all, of the coding sequences is replaced by such a disrupting sequence, preferably a lacZ sequence and a neomycin resistance sequence. Preferably, the genomic Stella/Fragilis sequence which is
15 functionally disrupted comprises a mouse Stella/Fragilis genomic sequence.

Preferably, such an animal expresses no Stella or Fragilis activity, or both. More preferably, the animal expresses no activity of the Stella or Fragilis proteins shown in the sequence listings. Stella/Fragilis knock-outs may be generated by various means known in the art, as described in further detail below. A specific
20 description of the construction of a Stella knock-out mouse is disclosed in Example 20 et seq below.

We further disclose a nucleic acid construct for functionally disrupting a Stella/Fragilis gene in a host cell. The nucleic acid construct comprises: a) a non-homologous replacement portion; b) a first homology region located upstream of the
25 non-homologous replacement portion, the first homology region having a nucleotide sequence with substantial identity to a first Stella/Fragilis gene sequence; and c) a second homology region located downstream of the non-homologous replacement portion, the second homology region having a nucleotide sequence with substantial identity to a second Stella/Fragilis gene sequence, the second Stella/Fragilis gene
30 sequence having a location downstream of the first Stella/Fragilis gene sequence in a

naturally occurring endogenous Stella/Fragilis gene. Additionally, the first and second homology regions are of sufficient length for homologous recombination between the nucleic acid construct and an endogenous Stella/Fragilis gene in a host cell when the nucleic acid molecule is introduced into the host cell. In a preferred embodiment, the non-homologous replacement portion comprises an expression reporter, preferably including lacZ and a positive selection expression cassette, preferably including a neomycin phosphotransferase gene operatively linked to a regulatory element(s).

Another aspect pertains to recombinant vectors into which the nucleic acid construct described above has been incorporated. Yet another aspect pertains to host cells into which the nucleic acid construct has been introduced to thereby allow homologous recombination between the nucleic acid construct and an endogenous Stella/Fragilis gene of the host cell, resulting in functional disruption of the endogenous Stella/Fragilis gene. The host cell can be a mammalian cell that normally expresses Stella/Fragilis from the liver, brain, spleen or heart, or a pluripotent cell, such as a mouse embryonic stem cell. Further development of an embryonic stem cell into which the nucleic acid construct has been introduced and homologously recombined with the endogenous Stella/Fragilis gene produces a transgenic nonhuman animal having cells that are descendant from the embryonic stem cell and thus carry the Stella/Fragilis gene disruption in their genome. Animals that carry the Stella/Fragilis gene disruption in their germline can then be selected and bred to produce animals having the Stella/Fragilis gene disruption in all somatic and germ cells. Such mice can then be bred to homozygosity for the Stella/Fragilis gene disruption.

25 ANTIBODIES

Antibodies, as used herein, refers to complete antibodies or antibody fragments capable of binding to a selected target, and including Fv, ScFv, Fab' and F(ab')₂, monoclonal and polyclonal antibodies, engineered antibodies including chimeric, CDR-grafted and humanised antibodies, and artificially selected

antibodies produced using phage display or alternative techniques. Small fragments, such as Fv and ScFv, possess advantageous properties for diagnostic and therapeutic applications on account of their small size and consequent superior tissue distribution.

5 The antibodies according described here are especially indicated for the detection of PGCs and other pluripotent cells, such as ES or EG cells. Accordingly, they may be altered antibodies comprising an effector protein such as a label. Especially preferred are labels which allow the imaging of the distribution of the antibody *in vivo* or *in vitro*. Such labels may be radioactive labels or radioopaque
10 labels, such as metal particles, which are readily visualisable within an embryo or a cell mass. Moreover, they may be fluorescent labels or other labels which are visualisable on tissue samples.

 Recombinant DNA technology may be used to improve the antibodies as described here. Thus, chimeric antibodies may be constructed in order to decrease
15 the immunogenicity thereof in diagnostic or therapeutic applications. Moreover, immunogenicity may be minimised by humanising the antibodies by CDR grafting [see European Patent Application 0 239 400 (Winter)] and, optionally, framework modification [EP 0 239 400].

 Antibodies may be obtained from animal serum, or, in the case of
20 monoclonal antibodies or fragments thereof, produced in cell culture. Recombinant DNA technology may be used to produce the antibodies according to established procedure, in bacterial or preferably mammalian cell culture. The selected cell culture system preferably secretes the antibody product.

 Therefore, we disclose a process for the production of an antibody
25 comprising culturing a host, e.g. *E. coli* or a mammalian cell, which has been transformed with a hybrid vector comprising an expression cassette comprising a promoter operably linked to a first DNA sequence encoding a signal peptide linked

in the proper reading frame to a second DNA sequence encoding said antibody protein, and isolating said protein.

Multiplication of hybridoma cells or mammalian host cells in vitro is carried out in suitable culture media, which are the customary standard culture media, for example Dulbecco's Modified Eagle Medium (DMEM) or RPMI 1640 medium, optionally replenished by a mammalian serum, e.g. foetal calf serum, or trace elements and growth sustaining supplements, e.g. feeder cells such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages, 2-aminoethanol, insulin, transferrin, low density lipoprotein, oleic acid, or the like. Multiplication of host cells which are bacterial cells or yeast cells is likewise carried out in suitable culture media known in the art, for example for bacteria in medium LB, NZCYM, NZYM, NZM, Terrific Broth, SOB, SOC, 2 x YT, or M9 Minimal Medium, and for yeast in medium YPD, YEPD, Minimal Medium, or Complete Minimal Dropout Medium.

In vitro production provides relatively pure antibody preparations and allows scale-up to give large amounts of the desired antibodies. Techniques for bacterial cell, yeast or mammalian cell cultivation are known in the art and include homogeneous suspension culture, e.g. in an airlift reactor or in a continuous stirrer reactor, or immobilised or entrapped cell culture, e.g. in hollow fibres, microcapsules, on agarose microbeads or ceramic cartridges.

Large quantities of the desired antibodies can also be obtained by multiplying mammalian cells in vivo. For this purpose, hybridoma cells producing the desired antibodies are injected into histocompatible mammals to cause growth of antibody-producing tumours. Optionally, the animals are primed with a hydrocarbon, especially mineral oils such as pristane (tetramethyl-pentadecane), prior to the injection. After one to three weeks, the antibodies are isolated from the body fluids of those mammals. For example, hybridoma cells obtained by fusion of suitable myeloma cells with antibody-producing spleen cells from Balb/c mice, or transfected cells derived from hybridoma cell line Sp2/0 that produce the desired

antibodies are injected intraperitoneally into Balb/c mice optionally pre-treated with pristane, and, after one to two weeks, ascitic fluid is taken from the animals.

The foregoing, and other, techniques are discussed in, for example, Kohler and Milstein, (1975) Nature 256:495-497; US 4,376,110; Harlow and Lane, 5 Antibodies: a Laboratory Manual, (1988) Cold Spring Harbor, incorporated herein by reference. Techniques for the preparation of recombinant antibody molecules is described in the above references and also in, for example, EP 0623679; EP 0368684 and EP 0436597, which are incorporated herein by reference.

The cell culture supernatants are screened for the desired antibodies, 10 preferentially by immunofluorescent staining of PGCs or other pluripotent cells, such as ES or EG cells, by immunoblotting, by an enzyme immunoassay, e.g. a sandwich assay or a dot-assay, or a radioimmunoassay.

For isolation of the antibodies, the immunoglobulins in the culture supernatants or in the ascitic fluid may be concentrated, e.g. by precipitation with 15 ammonium sulphate, dialysis against hygroscopic material such as polyethylene glycol, filtration through selective membranes, or the like. If necessary and/or desired, the antibodies are purified by the customary chromatography methods, for example gel filtration, ion-exchange chromatography, chromatography over DEAE-cellulose and/or (immuno-) affinity chromatography, e.g. affinity chromatography 20 with GCR1 or GCR2, or fragments thereof, or with Protein-A.

Hybridoma cells secreting the monoclonal antibodies are also provided. Preferred hybridoma cells are genetically stable, secrete monoclonal antibodies of the desired specificity and can be activated from deep-frozen cultures by thawing and recloning.

25 Also included is a process for the preparation of a hybridoma cell line secreting monoclonal antibodies directed to GCR1 and/or GCR2, characterised in that a suitable mammal, for example a Balb/c mouse, is immunised with a one or

more GCR1 or GCR2 polypeptides, or antigenic fragments thereof; antibody-producing cells of the immunised mammal are fused with cells of a suitable myeloma cell line, the hybrid cells obtained in the fusion are cloned, and cell clones secreting the desired antibodies are selected. For example spleen cells of Balb/c mice immunised with GCR1 and/or GCR2 are fused with cells of the myeloma cell line PAI or the myeloma cell line Sp2/0-Ag14, the obtained hybrid cells are screened for secretion of the desired antibodies, and positive hybridoma cells are cloned.

Preferred is a process for the preparation of a hybridoma cell line, characterised in that Balb/c mice are immunised by injecting subcutaneously and/or intraperitoneally between 10^6 and 10^7 and 10^8 cells expressing GCR1 and/or GCR2 and a suitable adjuvant several times, e.g. four to six times, over several months, e.g. between two and four months, and spleen cells from the immunised mice are taken two to four days after the last injection and fused with cells of the myeloma cell line PAI in the presence of a fusion promoter, preferably polyethylene glycol. Preferably the myeloma cells are fused with a three- to twentyfold excess of spleen cells from the immunised mice in a solution containing about 30 % to about 50 % polyethylene glycol of a molecular weight around 4000. After the fusion the cells are expanded in suitable culture media as described hereinbefore, supplemented with a selection medium, for example HAT medium, at regular intervals in order to prevent normal myeloma cells from overgrowing the desired hybridoma cells.

Recombinant DNAs comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of antibodies directed to GCR1 and/or GCR2 as described hereinbefore are also disclosed. By definition such DNAs comprise coding single stranded DNAs, double stranded DNAs consisting of said coding DNAs and of complementary DNAs thereto, or these complementary (single stranded) DNAs themselves.

Furthermore, DNA encoding a heavy chain variable domain and/or for a light chain variable domain of antibodies directed to GCR1 and/or GCR2 can be

enzymatically or chemically synthesised DNA having the authentic DNA sequence coding for a heavy chain variable domain and/or for the light chain variable domain, or a mutant thereof. A mutant of the authentic DNA is a DNA encoding a heavy chain variable domain and/or a light chain variable domain of the above-mentioned antibodies in which one or more amino acids are deleted or exchanged with one or more other amino acids. Preferably said modification(s) are outside the CDRs of the heavy chain variable domain and/or of the light chain variable domain of the antibody. Such a mutant DNA is also intended to be a silent mutant wherein one or more nucleotides are replaced by other nucleotides with the new codons coding for the same amino acid(s). Such a mutant sequence is also a degenerated sequence. Degenerated sequences are degenerated within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without resulting in a change of the amino acid sequence originally encoded. Such degenerated sequences may be useful due to their different restriction sites and/or frequency of particular codons which are preferred by the specific host, particularly *E. coli*, to obtain an optimal expression of the heavy chain murine variable domain and/or a light chain murine variable domain.

The term mutant is intended to include a DNA mutant obtained by in vitro mutagenesis of the authentic DNA according to methods known in the art.

For the assembly of complete tetrameric immunoglobulin molecules and the expression of chimeric antibodies, the recombinant DNA inserts coding for heavy and light chain variable domains are fused with the corresponding DNAs coding for heavy and light chain constant domains, then transferred into appropriate host cells, for example after incorporation into hybrid vectors.

Also disclosed are recombinant DNAs comprising an insert coding for a heavy chain murine variable domain of an antibody directed to GCR1 and/or GCR2 fused to a human constant domain γ , for example $\gamma 1$, $\gamma 2$, $\gamma 3$ or $\gamma 4$, preferably $\gamma 1$ or $\gamma 4$. Likewise we also describe recombinant DNAs comprising an insert coding for a

light chain murine variable domain of an antibody directed to GCR1 and/or GCR2 fused to a human constant domain κ or λ , preferably κ .

In another embodiment, we disclose recombinant DNAs coding for a recombinant polypeptide wherein the heavy chain variable domain and the light chain variable domain are linked by way of a spacer group, optionally comprising a signal sequence facilitating the processing of the antibody in the host cell and/or a DNA coding for a peptide facilitating the purification of the antibody and/or a cleavage site and/or a peptide spacer and/or an effector molecule.

The DNA coding for an effector molecule is intended to be a DNA coding for the effector molecules useful in diagnostic or therapeutic applications. Thus, effector molecules which are toxins or enzymes, especially enzymes capable of catalysing the activation of prodrugs, are particularly indicated. The DNA encoding such an effector molecule has the sequence of a naturally occurring enzyme or toxin encoding DNA, or a mutant thereof, and can be prepared by methods well known in the art.

ANTI-PEPTIDE STELLA AND FRAGILIS ANTIBODIES

Anti-peptide antibodies are produced against Stella and Fragilis peptide sequences. The sequences chosen are as follow:

GCR1 (Fragilis): ASGGQPPNYERIKEEYE and
RDRKMVGDTVGAQAYA

GCR2 (Stella): MEEPSEKVDPMKDPET and CHYQRWDPSENAKIGKN

Antibodies are produced by injection into rabbits, and other conventional means, as described in for example, Harlow and Lane (supra).

Antibodies are checked by Elisa assay and by Western blotting, and used for immunostaining as described in the Examples.

DETECTION OF PLURIPOTENT CELLS IN CELL POPULATIONS

Polynucleotide probes or antibodies as described here may be used for the
 5 detection of pluripotent cells such as primordial germ cells (PGCs), stem cells such as embryonic stem (ES) and embryonic germ (EG) cells in cell populations. As used herein, a “cell population” is any collection of cells which may contain one or more PGCs, ES or EG cells. Preferably, the collection of cells does not consist solely of PGCs, but comprises at least one other cell type.

10 Cell populations comprise embryos and embryo tissue, but also adult tissues and tissues grown in culture and cell preparations derived from any of the foregoing.

Polynucleotides as described here may be used for detection of GCR1 and GCR2 transcripts in PGCs or other pluripotent cells, such as ES or EG cells, by nucleic acid hybridisation techniques. Such techniques include PCR, in which
 15 primers are hybridised to GCR1 and/or GCR2 transcripts and used to amplify the transcripts, to provide a detectable signal; and hybridisation of labelled probes, in which probes specific for a unique sequence in the GCR1 and/or GCR2 transcript are used to detect the transcript in the target cells.

As noted hereinbefore, probes may be labelled with radioactive,
 20 radioopaque, fluorescent or other labels, as is known in the art.

The antibodies may also be used to detect GCR1 and/or GCR2. GCR1, in particular, possesses an extracellular domain which may be targeted by an anti-GCR1 antibody and detected at the cell surface. Alternatively, intracellular scFv may be used to detect GCR1 and/or GCR2 within the cell.

Particularly indicated are immunostaining and FACS techniques. Suitable fluorophores are known in the art, and include chemical fluorophores and fluorescent polypeptides, such as GFP and mutants thereof (see WO 97/28261). Chemical fluorophores may be attached to immunoglobulin molecules by
 5 incorporating binding sites therefor into the immunoglobulin molecule during the synthesis thereof.

Preferably, the fluorophore is a fluorescent protein, which is advantageously GFP or a mutant thereof. GFP and its mutants may be synthesised together with the immunoglobulin or target molecule by expression therewith as a fusion polypeptide,
 10 according to methods well known in the art. For example, a transcription unit may be constructed as an in-frame fusion of the desired GFP and the immunoglobulin or target, and inserted into a vector as described above, using conventional PCR cloning and ligation techniques.

Antibodies may be labelled with any label capable of generating a signal.
 15 The signal may be any detectable signal, such as the induction of the expression of a detectable gene product. Examples of detectable gene products include bioluminescent polypeptides, such as luciferase and GFP, polypeptides detectable by specific assays, such as β -galactosidase and CAT, and polypeptides which modulate the growth characteristics of the host cell, such as enzymes required for metabolism
 20 such as HIS3, or antibiotic resistance genes such as G418. In a preferred aspect, the signal is detectable at the cell surface. For example, the signal may be a luminescent or fluorescent signal, which is detectable from outside the cell and allows cell sorting by FACS or other optical sorting techniques.

Preferred is the use of optical immunosensor technology, based on optical
 25 detection of fluorescently-labelled antibodies. Immunosensors are biochemical detectors comprising an antigen or antibody species coupled to a signal transducer which detects the binding of the complementary species (Rabbany *et al.*, 1994 *Crit Rev Biomed Eng* **22**:307-346; Morgan *et al.*, 1996 *Clin Chem* **42**:193-209). Examples of such complementary species include the antigen Zif 268 and the anti-

Zif 268 antibody. Immunosensors produce a quantitative measure of the amount of antibody, antigen or hapten present in a complex sample such as serum or whole blood (Robinson 1991 *Biosens Bioelectron* **6**:183-191). The sensitivity of immunosensors makes them ideal for situations requiring speed and accuracy

5 (Rabbany *et al.*, 1994 *Crit Rev Biomed Eng* **22**:307-346).

Detection techniques employed by immunosensors include electrochemical, piezoelectric or optical detection of the immunointeraction (Ghindilis *et al.*, 1998 *Biosens Bioelectron* **1**:113-131). An indirect immunosensor uses a separate labelled species that is detected after binding by, for example, fluorescence or luminescence

10 (Morgan *et al.*, 1996 *Clin Chem* **42**:193-209). Direct immunosensors detect the binding by a change in potential difference, current, resistance, mass, heat or optical properties (Morgan *et al.*, 1996 *Clin Chem* **42**:193-209). Indirect immunosensors may encounter fewer problems due to non-specific binding (Attridge *et al.*, 1991 *Biosens Bioelectron* **6**:201-214; Morgan *et al.*, 1996 *Clin Chem* **42**:193-209).

15 FURTHER ASPECTS OF THE INVENTION

We provide a nucleic acid molecule which is at least 90% homologous to SEQ ID NO: 1 and a nucleic acid molecule which is at least 75% homologous to SEQ ID NO: No. 3.

We disclose polynucleotides which comprise a contiguous stretch of

20 nucleotides from SEQ ID NO: 1 or SEQ ID NO: 3, or any of SEQ ID NOs: 5 to 9, or of a sequence at least 90% homologous thereto. Advantageously, this stretch of contiguous nucleotides is 50 nucleotides in length, preferably 40, 35, 30, 25, 20, 15 or 10 nucleotides in length.

The genes GCR1 and GCR2 encode novel polypeptides, the sequences of

25 which are set forth in SEQ ID NO: 2 and SEQ ID NO: 4. We therefore disclose polypeptides encoded by the nucleic acids described here. Preferably, the polypeptides have the sequences set forth in SEQ ID NO: 2 and SEQ ID NO: 4.

Moreover, we provide a method by which genes specifically expressed in PGCs or other pluripotent cells, such as ES or EG cells, may be isolated, comprising the steps of: (a) providing a population of cells containing PGCs or other pluripotent cells, such as ES or EG cells; (b) isolating one or more PGCs or other pluripotent
5 cells, such as ES or EG cells, therefrom and providing single-cell isolates; (c) amplifying the transcribed nucleic acid present in a single cell; (d) conducting a subtractive hybridisation screen to identify transcripts present in the PGCs or other pluripotent cells, such as ES or EG cells, but not in somatic cells; and (e) probing a nucleic acid library with one or more transcripts identified in d) to clone one or more
10 genes which are specifically expressed.

Further aspects of the invention are now set out in the following numbered paragraphs; it is to be understood that the invention encompasses these aspects:

Paragraph 1. A nucleic acid having at least 90% homology with the sequence set forth in SEQ. ID. No. 1.

15 Paragraph 2. A nucleic acid having at least 75% homology with the sequence set forth in SEQ. ID. No. 3.

Paragraph 3. A nucleic acid comprising a sequence of 25 contiguous nucleotides of the nucleic acid of Paragraph 1 or Paragraph 2.

20 Paragraph 4. A nucleic acid comprising a sequence of 15 contiguous nucleotides of the nucleic acid of Paragraph 1 or Paragraph 2.

Paragraph 5. The complement of a nucleic acid sequence according to any preceding Paragraph.

Paragraph 6. A nucleic acid according to any one of Paragraphs 1 to 5, comprising one or more nucleotide substitutions, wherein such substitutions do not

alter the coding specificity of said nucleic acid as a result of the degeneracy of the genetic code.

Paragraph 7. A polypeptide encoded by a nucleic acid according to any preceding Paragraph.

5 Paragraph 8. A method for identifying a primordial germ cell in a population of cells, comprising detecting the expression of a nucleic acid sequence according to Paragraph 1 or Paragraph 2, or a homologue thereof.

Paragraph 9. A method according to Paragraph 8, comprising the steps of amplifying nucleic acids from putative PGCs using 5' and 3' primers specific for
10 GCR1 and/or GCR2, and detecting amplified nucleic acid thus produced.

Paragraph 10. A method according to Paragraph 8, wherein the expression of the nucleic acid sequence is detected by *in situ* hybridisation.

Paragraph 11. A method according to Paragraph 8, wherein the expression of the nucleic acid sequence is determined by detecting the protein product encoded
15 thereby.

Paragraph 12. A method according to Paragraph 11, wherein the protein product is detected by immunostaining.

Paragraph 13. An antibody specific for a polypeptide according to Paragraph 7.

20 Paragraph 14. An antibody according to Paragraph 13, specific for the extracellular domain of GCR1.

Paragraph 15. Use of an antibody according to Paragraph 13 or Paragraph 14 for the identification of a PGC in a population of cells.

Paragraph 16. A PGC when identified by a method according to any one of Paragraphs 8 to 12.

Paragraph 17. A method for isolating a gene specifically expressed in PGCs, comprising the steps of: a) providing a population of cells containing PGCs; b)
5 isolating one or more PGCs therefrom and providing single-cell PGC isolates; c) amplifying the transcribed nucleic acid present in a single PGC; d) conducting a subtractive hybridisation screen to identify transcripts present in PGCs but not in somatic cells; and e) probing a nucleic acid library with one or more transcripts identified in d) to clone one or more genes which are specifically expressed in
10 PGCs.

Paragraph 18. A GCRI polypeptide, or a fragment, homologue, variant or derivative thereof.

Paragraph 19. A polypeptide according to paragraph 18, which has at least 50%, 60%, 70%, 80%, 90% or 95% homology to a sequence shown in SEQ ID NO:
15 2.

Paragraph 20. A GCR2 polypeptide, or a fragment, homologue, variant or derivative thereof.

Paragraph 21. A polypeptide according to paragraph 20, which has at least 50%, 60%, 70%, 80%, 90% or 95% homology to a sequence shown in SEQ ID NO:
20 4.

Paragraph 22. A nucleic acid encoding a polypeptide according to any preceding paragraph.

Paragraph 23. A nucleic acid having at least 90% homology with the sequence set forth in SEQ ID NO: 1, or a fragment, variant or derivative thereof.

Paragraph 24. A nucleic acid having at least 75% homology with the sequence set forth in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9 or a fragment, variant or derivative thereof.

Paragraph 25. A nucleic acid comprising a sequence of 25 contiguous nucleotides of a nucleic acid according to paragraph 22, 23 or 24.

Paragraph 26. A nucleic acid comprising a sequence of 15 contiguous nucleotides of a nucleic acid according to any of paragraphs 22 to 25.

Paragraph 27. The complement of a nucleic acid sequence according to any of paragraphs 22 to 26.

Paragraph 28. A nucleic acid according to any of paragraphs 22 to 27, comprising one or more nucleotide substitutions, wherein such substitutions do not alter the coding specificity of said nucleic acid as a result of the degeneracy of the genetic code.

Paragraph 29. A polypeptide encoded by a nucleic acid according to any preceding paragraph.

Paragraph 30. A polypeptide according to paragraph 29, in which the polypeptide comprises a sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4.

Paragraph 31. A method for identifying a pluripotent cell, comprising detecting the presence of a polypeptide according to any of paragraphs 18 to 21, 29 or 30 or the expression of a nucleic acid according to any of paragraphs 22 to 28, or a homologue thereof.

Paragraph 32. A method according to paragraph 31, comprising the steps of amplifying nucleic acids from a putative pluripotent cell using 5' and 3' primers specific for GCRI and/or GCR2, and detecting amplified nucleic acid thus produced.

Paragraph 33. A method according to paragraph 31, wherein the expression of the nucleic acid sequence is detected by in situ hybridisation.

Paragraph 34. A method according to paragraph 25, wherein the expression of the nucleic acid sequence is determined by detecting the protein product encoded
5 thereby.

Paragraph 35. A method according to paragraph 31 or paragraph 34, wherein the protein product is detected by immunostaining.

Paragraph 36. An antibody specific for a polypeptide according to any of paragraphs 18 to 21, 29 or 30.

10 Paragraph 37. An antibody according to paragraph 36, which is capable of specifically binding to an extracellular domain of GCRL.

Paragraph 38. Use of an antibody according to paragraph 36 or paragraph 37 for the identification and/ or isolation of a pluripotent cell.

15 Paragraph 39. A pluripotent cell identified by a method according to any one of paragraphs 31 to 35 and 38.

Paragraph 40. A method for isolating a gene specifically expressed in a pluripotent cell, comprising the steps of (a) providing a population of cells containing a pluripotent cell; (b) isolating one or more pluripotent cells therefrom and providing single-cell pluripotent cell isolates; (c) amplifying the transcribed
20 nucleic acid present in a single pluripotent cell; (d) conducting a subtractive hybridisation screen to identify transcripts present in pluripotent cells but not in somatic cells; and (e) probing a nucleic acid library with one or more transcripts identified in (d) to clone one or more genes which are specifically expressed in pluripotent cells.

Paragraph 41. A method according to any of paragraphs 31 to 35 or 40, a use according to paragraph 38, a pluripotent cell according to paragraph 40, in which the pluripotent cell is selected from the group consisting of: a primordial germ cell (PGC), an embryonic stem cell (ES) and an embryonic germ cell (EG).

5 Paragraph 42. A transgenic non-human animal comprising a nucleic acid according to any of paragraphs 18 to 28.

Paragraph 43. A transgenic non-human animal according to paragraph 42 which is a mouse.

10 Paragraph 44. A cell or tissue from a transgenic non-human animal according to paragraph 42.

Paragraph 45. Use of a transgenic non-human animal according to Claim 42, or a cell or tissue according to paragraph 44, in a method of identifying a compound which is capable of interacting specifically with a Stella or Fragilis protein.

15 Paragraph 46. A non-human transgenic animal, characterised in that the transgenic animal comprises an altered Stella gene or an altered Fragilis gene, or both.

20 Paragraph 47. A non-human transgenic animal according to Claim 46, in which the alteration is selected from the group consisting of: a deletion of Stella and/or Fragilis, a mutation in Stella and/or Fragilis resulting in loss of function, introduction of an exogenous gene having a nucleotide sequence with targeted or random mutations into Stella and/or Fragilis, introduction of an exogenous gene from another species into Stella and/or Fragilis, and a combination of any of these.

Paragraph 48. A non-human transgenic animal having a functionally disrupted endogenous Stella and/or Fragilis gene, in which the transgenic animal

preferably comprises in its genome and expresses a transgene encoding a heterologous Stella and/or Fragilis protein.

Paragraph 49. A nucleic acid construct for functionally disrupting a Stella and/or Fragilis gene in a host cell, the nucleic acid construct comprising: (a) a non-homologous replacement portion; (b) a first homology region located upstream of the non-homologous replacement portion, the first homology region having a nucleotide sequence with substantial identity to a first Stella and/or Fragilis gene sequence; and (c) a second homology region located downstream of the non-homologous replacement portion, the second homology region having a nucleotide sequence with substantial identity to a second Stella and/or Fragilis gene sequence, the second Stella and/or Fragilis gene sequence having a location downstream of the first Stella and/or Fragilis gene sequence in a naturally occurring endogenous Stella and/or Fragilis gene.

EXAMPLES

Example 1. Identification of Genes Specific to the Earliest Population of Primordial Germ Cells (PGCs) by Single Cell cDNA Differential Screening

5 A method for single cell analysis is developed to identify genes that are involved in the specification of the germ cell lineage, which results in the establishment of a founder population of Primordial Germ Cells (PGCs). It is determined that the lineage specification of PGCs accompanies the expression of a unique set of genes, which are not expressed in somatic cells.

10 The method for the identification of the genes is mainly based on the differential screening of the libraries made from single cells from day 7.25 mouse embryonic fragments that contain PGCs. The single cell cDNA differential screen was originally described by Brady and Iscove (1993), and subsequently modified by Cathaline Dulac and Richard Axel which resulted in the successful identification of the pheromone receptor genes from rat (Dulac, C. and Axel, 1995). The method of Axel's group is
15 employed, with slight modifications as described.

Construction of single cell cDNAs from embryonic fragment bearing the earliest population of PGCs

In the mouse, the earliest population of the PGCs is reported to consist of alkaline phosphatase positive cluster of some 40 cells, at the base of the emerging allantois at day
20 7.25 of gestation (Ginsburg, M., Snow, M.H.L., and McLaren, A. (1990)). The precise location of the PGC cluster in the inbred 129Sv and C57BL/6 strain is determined by microscopy using both whole-mount alkaline phosphatase staining and semi-thin sections stained by methylene blue. The earliest stage at which a cluster of PGCs can be detected is at the Late Streak stage (Downs, K.M., and Davies, T. (1993)), when a distinctively
25 stained population of cells is found just beneath an epithelial lining from which the allantoic bud appears. This region is at the border between the extraembryonic and embryonic tissues just posterior to and above the most proximal part of the primitive streak. The cluster persists at this position at least until Early/Mid Bud stage. In the inbred

129Sv strain, the PGC cluster is found to contain a slightly larger number of the cells, which are more tightly packaged than in the C57BL/6 strain. The 129Sv strain is used for subsequent experiments, as a better recovery of the earliest PGCs is obtained.

129Sv embryos are isolated at E7.5 in DMEM plus 10% FCS buffered with
5 25mM HEPES at room temperature and the developmental stage of each embryo is determined under a dissection microscope. The precise developmental stage can differ substantially even amongst embryos within the same litter. Embryos that are at the no bud or early bud (allantoic) stage are chosen for further dissection, which in part is dictated by the ease of identification of the region containing PGCs as seen under the dissection
10 microscope. The fragment that is expected to contain the PGC cluster is cut out very precisely by means of solid glass needles. This region is dissociated into single cells using 0.25% trypsin-1mM EGTA/PBS treatment at 37°C for 10 min, followed by gentle pipetting with a mouth pipette. The dissected fragment usually contained between 250-300 cells. The procedure for cell dispersal with this gentle procedure left the visceral
15 endoderm layer remained as an intact cellular sheet.

We picked single cells randomly from the cell suspension by a mouth pipette and put individual single cells (but avoiding generating air bubbles), into a thin-walled PCR tube containing 4µl of ice-cold cell lysis buffer (50mM Tris-HCl pH8.3, 75mM KCl, 3mM MgCl₂, 0.5% NP-40, containing 80ng/ml pd(T)24, 5µg/ml prime RNase inhibitor,
20 324U/ml RNA guard, and 10mM each of dATP, dCTP, dGTP, and dTTP). The volume of medium carried with the single cell is less than 0.5µl. The tube is briefly centrifuged to ensure that the cell is indeed in the lysis buffer. During each separate experiment, we picked a total of 19 single cells, and left one tube without a cell, to serve as a negative control for the PCR amplification procedure. All the cells that are collected in tubes are
25 kept on ice before starting the subsequent procedure.

The cells are lysed by incubating the tubes at 65°C for 1min, and then kept at room temperature for 1-2 min to allow the oligo dT to anneal to RNA. First-strand cDNA synthesis is initiated by adding 50U of Moloney murine leukaemia virus (MMLV) and 0.5U of avian myeloblastosis virus (AMV) reverse transcriptase followed by
30 incubation for 15min at 37°C. The reverse transcriptases are inactivated for 10min at

65°C. This reverse transcription reaction is restricted to 15 min, which allows the synthesis of relatively uniform size cDNAs of between 500 base -1000 bases in length from the C termini. This enables the subsequent PCR amplification to be fairly representative.

5 Next, in order to add the poly A tail to the 5 prime end of the synthesised first-strand cDNA, 4.5µl of 2X tailing buffer (200mM potassium cacodylate pH7.2, 4mM CoCl₂, 0.4mM DTT, 200mM dATP containing 10U of terminal transferase) is added to the reaction followed by incubation for 15min at 37 °C. The samples are heat inactivated for 10 min at 65°C. The reaction now contained synthesised cDNAs bearing poly T tail at
10 their C termini and poly A stretch at their N termini, ready for the amplification by the PCR using the specific primer.

 The contents of each tube is brought to 100µl with a solution made of 10mM Tris-HCl pH8.3, 50mM KCl, 2.5mM MgCl₂, 100µg/ml bovine serum albumin, 0.05% Triton-X 100, 1mM of dATP, dCTP, dGTP, dTTP, 10U of Taq polymerase, and 5µg of the AL1
15 primer. The AL1 sequence is ATT GGA TCC AGG CCG CTC TGG ACA AAA TAT GAA TCC (T)₂₄. The PCR amplification is performed according to the following schedule: 94°C for 1 min, 42°C for 2 min, and 72°C for 6 min with 10 s extension per cycle for 25 cycles. Five additional units of Taq polymerase are added before performing 25 more cycles with the same programme but without the extension time. Each tube at
20 this point contains amplified cDNA products derived from a single cell. The protein contents of the solution are extracted by phenol/chloroform treatment, and the amplified cDNAs are precipitated by ethanol and eventually suspended in 100µl of TE pH8.0. 5µl of the cDNA solution is run on a 1.5% agarose gel to check the success of the amplification. Most of the samples show a very intense 'smeared' band ranging mainly
25 between 500bp to 1200bp, indicating the efficient amplification of the single cell cDNA. Only the successfully amplified samples are used for the subsequent 'cell typing' analysis.

Example 2. Identification of PGCs by Examination of the Expression of Marker Genes

The embryonic fragment which is excised theoretically contains three major components: the allantoic mesoderm, PGCs, and extraembryonic mesoderm surrounding PGCs. In order to identify the single cell cDNA of PGC origin amongst these samples, positive and negative selection of the constructed cDNAs is performed, by examining the expression of four marker genes (BMP4, TNAP, Hoxb1, and Oct4), which are known to be either expressed or repressed in various cell types in this region.

At the No/Early Bud stage, BMP4 is reported to be expressed in the emerging allantois and mesodermal components of the developing amnion, chorion, and visceral yolk sac (Lawson, K.A., Dunn, N.R., Roelen, B.A.J., Zeinstra, L.M., Davis, A.M., Wright, C.V.E., Korving, J.P.W.F.M., and Hogan, B.L.M. (1999)). The boundary of BMP4 expression is very sharp, and the expression is completely excluded in the mesodermal region beneath the epithelial lining continuous from the amnionic mesoderm where the putative PGCs are determined. Therefore, BMP4 is used as a negative marker for the selection. Primer pairs are designed for amplifying the C terminal portion of BMP4 (5': GCC ATA CCT TGA CCC GCA GAA G, 3': AAA TGG CAC TCA GTT CAG TGG G). The PCR amplification is performed using 0.5µl of the cDNA solution as a template according to the following schedule: 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min for 20 cycles. Among 83 samples tested, 57 samples show the expected size of bands, indicating expression of BMP4 these single cells. These samples are considered to be of allantoic mesodermal origin, and therefore excluded from amongst the candidates representing cells of PGC origin.

The expression of tissue non-specific alkaline phosphatase (TNAP), which has long been used as an early marker for PGCs (Ginsburg, M., Snow, M.H.L., and McLaren, A. (1990)), is then examined. Primer pairs are designed (5': CCC AAA GCA CCT TAT TTT TCT ACC, 3': TTG GCG AGT CTC TGC AAT TGG) and the same PCR reaction as above is performed. Amongst the 26 samples, 22 samples are judged to be positive for TNAP. From the alkaline phosphatase staining of the sectioned embryos, it is known that the somatic cells surrounding PGCs also express some amount of TNAP, although the

level of expression is slightly lower than that in PGCs. Therefore, amongst these 22 positive samples there should be still be cells destined to become somatic cells as well as PGCs.

One of the genes known to be expressed in the totipotent PGCs but not in somatic cells is Oct4 (Yoem, Y.II., Fuhrmann, G., Ovitt, C.E., Brehm, A., Ohbo, K., Gross, M., Hubner, K., and Scholer, H.R. (1996)). To examine the possibility that Oct4 can be used as a marker to distinguish PGCs from somatic cells at this stage, Oct4 expression is checked in the 22 samples by PCR (5': CAC TCT ACT CAG TCC CTT TTC, 3': TGT GTC CCA GTC TTT ATT TAA G). All the 22 samples express Oct4 at comparable levels, indicating that the somatic cells at this stage are still actively transcribing Oct4 RNA.

The amount of expression of TNAP is quantitated in 22 samples by Southern blot analysis (reverse northern blot analysis). Given the fairly representative amplification of the single cell method, confirmed by amplifying single ES cell cDNA, Southern blot analysis allows semi-quantitative measurement of the amount of the genes expressed in the original single cells, although it does not serve as a perfect indicator of cell identity. However, as a result of this TNAP analysis, 10 samples out of 22 show relatively stronger bands at an equivalent level, while the remaining 12 samples exhibit weaker signals. These results indicate that these 22 samples can be divided at least into two groups, one with stronger TNAP expression (therefore from putative PGCs) and the other with weaker TNAP.

The possibility that somatic cells surrounding PGCs start to express Hoxb1, while PGCs do not (personal communication from Dr. Kirstie Lawson) is also examined. Primer pairs are designed (5': AAC TCA TCA GAG GTC GAA GGA, 3': CGG TGC TAT TGT AAG GTC TGC) and the same PCR reaction as above is performed. Among the 22 samples tested, 12 are positive, and more importantly, these 12 samples perfectly match the ones which show weaker TNAP signals, by Southern blot analysis.

Taking all these results into consideration, it is concluded that 10 samples out of 83, which are Oct4 (+), TNAP (++), BMP4 (-), and Hoxb1(-), are of PGC origin. This

ratio (10/83) is reasonable, considering the number of the founding population of PGCs as 40 and the number of cells in the fragment as 250-300.

Example 3. Differential Screening of Single Cell cDNA Libraries

As the efficiency of the amplification of cDNA differs in each tube, it is very
5 important to select the samples with the most efficiently amplified cDNA for the
construction of libraries. The amplification of six different genes (ribosomal protein S12,
intermediate filament protein vimentin, β tubulin-5, α actin, Oct4, E-cadherin) is
examined in the 10 PGC candidate samples, by Southern blot analysis. Judging from the
overall profile of the amplification of all these six genes, three cDNA preparations are
10 selected for the construction of libraries.

To obtain the maximum amount of double strand cDNA, an extension step is
performed with 5 μ l of cell cDNA in 100 μ l of the PCR buffer described as above
(including 1 μ l of Amplitaq) according to the following schedule: 94°C for 5min, 42°C for
5min, 72°C for 30min. The solution is extracted by phenol/chloroform treatment, and the
15 amplified cDNAs are precipitated by ethanol, suspended in TE, and completely digested
with EcoRI. The PCR primer and excess amount of dNTPs are removed by QIAGEN
PCR Purification Kit, and all the purified cDNAs are run on a 2% low melting agarose
gel. cDNAs above 500bp are cut and purified by QIAGEN Gel Purification Kit. The
purified cDNAs are precipitated by ethanol and suspended in TE and ligated into λ ZAP
20 II vector arms. The ligated vector is packaged, titered and the ratio of the successfully
ligated clones is monitored by amplifying the inserts with T3 and T7 primers from 20
plaques. More than 95% of the phage are found to contain inserts.

The representation of the three genes, ribosomal protein S12, β tubulin-5, Oct4, is
quantitated by screening 5000 plaques, and the library of the best quality among the three
25 (S12 0.62%, β tubulin 0.4%, Oct4 0.5%) is used for the differential screening. As a
comparison partner with the PGC probe, one of the most efficiently amplified
surrounding somatic cell cDNA (Oct4 (+), TNAP(+/-), BMP(-), and Hoxb1(+)) is
selected by the similar Southern blot analysis.

The library is plated at a density of 1000 plaques per 15cm dish to obtain large plaques (2mm diameter) and two duplicate lifts are taken using Hybond N+ filters from Amersham. The filters are prehybridized at 65°C in 0.5M sodium phosphate buffer (pH7.3) containing 1% bovine serum albumin and 4% SDS. We prepared the cell cDNA probes by reamplifying for 10 cycles 1µl of the original cell cDNA into 50µl of total reaction with the AL1 primer, in the absence of cold dCTP and with 100µCi of newly received ³²PdCTP, followed by the purification using Amersham NickTM Spin Column. The filters are hybridised for at least 16 hrs with 1.0X10⁷cpm/ml (The first filter is hybridised with somatic cell probe and the second filter is hybridised with the PGC probe). After the hybridisation, the filters are washed three times at 65°C in 0.5X SSC, 0.5% SDS and exposed to X ray films until the appropriate signal is obtained (usually one to two days).

The positive plaques in the two duplicate filters are compared very carefully. Among 5000 plaques screened, 280 are picked as candidates representing the differentially expressed genes. The inserts of all the 280 plaques are amplified with T3 and T7 primers, run on 1.5% gels, and double sandwich Southern blotted. Each membrane is hybridised with the PGC and somatic cell probe, respectively, using the same conditions as the screening. 38 clones amongst the 280 are selected as differentially expressed genes. These clones are next hybridised with the second PGC and somatic cell cDNA probes, which resulted in 20 clones out of 38 to be common in both PGC cDNAs but they are either not included or less abundant in both somatic cell cDNAs. The sequences of all the 20 clones are determined.

Genes highly specific to the earliest population of PGCs

The 20 clones represent 11 different genes (two clones appear two times, one clone appears three times, and one clone appears 6 times). To further stringently check the specificity of expression, primer pairs are designed for these 11 clones and their expression checked in 10 different single PGC-candidate cDNAs and 10 different single somatic cell cDNAs by PCR. Two of them show highly specific expression to PGC cDNAs.

The first gene, GCR1 (Germ cell restricted-1, Fragilis), encodes a 137 amino acid protein with a predicted molecular weight of 15.0kD. Nucleotide and amino acid sequences of mouse Fragilis are shown in **Figure 1**.

The best fit model of the EMBL program PredictProtein predicts two
5 transmembrane domains, both N and C terminus ends being located outside. The BLASP search revealed that Fragilis is a novel member of the interferon-inducible protein family. One prototype member, human 9-27 (identical to Leu-13 antigen), is inducible by interferon in leukocytes and endothelial cells, and is located at the cell surface as a component of a multimeric complex involved in the transduction of antiproliferative and
10 homotypic adhesion signals (Deblandre, 1995). The BLASTN search revealed that the Fragilis sequence was found in ESTs derived from many different tissues both from embryos and adults, indicating that Fragilis may play a common role in different developmental and cell biological contexts. Database searches reveal a sequence match with the rat interferon-inducible protein (sp:INIB RAT, pir:JC1241) with unknown
15 function. The GCR1 sequence appears six times in our screen, indicating high level expression in PGCs.

The second gene, GCR2, (Stella) encodes a 150 amino acid protein, of 18kD. Nucleotide and amino acid sequences of mouse Fragilis are shown in **Figure 2**.

It has no sequence homology with any known protein, contains several nuclear
20 localisation consensus sequences and is highly basic pI (pI=9.67, the content of basic residues=23.3%), indicating a possible affinity to DNA. Furthermore a potential nuclear export signal was identified, indicating that Stella may shuttle between the nucleus and the cytoplasm. BLASTN analysis revealed that the Stella sequence was found only in the preimplantation embryo and germ line (newborn ovary, female 12.5 mesonephros and
25 gonad etc.) ESTs indicating its predominant expression in totipotent and pluripotent cells. Interestingly, we found that Stella contains in its N terminus a modular domain which has some sequence similarity with the SAP motif. This motif is a putative DNA-binding domain involved in chromosomal organisation. Furthermore, the SMART program revealed the presence of a splicing factor motif-like structure in its C-terminus, These

findings indicate a possible involvement of Stella in chromosomal organization and RNA processing.

Example 4. Identification of PGCs by Screening for GCR1 and GCR2 Expression

Although PGCs are identified in Example 2 by analysis of BMP4, TNAP, Hoxb1,
5 and Oct4, no single one of these genes can be taken as a marker for the PGC state.
However, both GCR1 and GCR2 may be used as such.

The expression of GCR1 is examined. Primer pairs are designed (5':
CTACTCCGTGAAGTCTAGG, 3': AATGAGTGTTACACCTGCGTG) and the same
PCR reaction as above is performed. GCR1 expression was detected in germ cell
10 competent cells. The definitive PGCs were recruited from amongst this group of cells
showing expression of GCR1.

The boundary of GCR2 expression in particular is well-defined, and the
expression is substantially limited to PGCs. Therefore, GCR2 is used as a positive marker
for the selection of PGCs. Primer pairs are designed for amplifying the C terminal portion
15 of GCR2 (5': GCCATTCAGATGTCTCTGCAC, 3':
CTCACAGCTTGAGGCTTCTAA). The PCR amplification is performed using 0.5µl of
the cDNA solution obtained from PGCs in Example 1 as a template according to the
following schedule: 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min for 20 cycles.
Among 83 samples tested, only those taken from PGCs show expression of GCR2.
20 Hence, GCR2 is a positive marker for the PGC fate.

Antibodies against GCR1 and GCR2 can be similarly used to detect pluripotent
cells. Preferably, antibodies against GCR1 are used to detect germ cell competent cells,
and antibodies against GCR2 are used to detect PGCs.

Accordingly, both GCR1 and GCR2 are positive markers for the PGC fate which
25 can be used to positively identify PGC.

Identification of PGC by ISH

The *in vivo* expression of the two genes is examined by *in situ* hybridisation. The expression of GCR1 starts very weakly in the entire epiblast at E6.0-E6.5 (PreStreak stage) and becomes strong in the few cell layers of the proximal rim of the epiblast.

- 5 BMP4 that is expressed in the extraembryonic ectoderm is one signalling molecule that is important for the induction of germ cell competence and expression of GCR1. Other signals, such as interferons are likely to be involved in the induction of GCR1. The expression becomes more intense at the proximo-posterior end of the developing primitive streak at the Early/Mid Streak stage and becomes very strong at this position
- 10 from Late Streak stage onward. The expression persists until Early Head Fold stage and eventually disappears gradually. No expression is detected in the migrating PGCs at E8.5.

- The expression of GCR2 starts at the proximo-posterior end of the developing primitive streak at Mid/Late Streak stage and becomes gradually strong at the same position from the later stage onward. The expression is specific and individual single cells
- 15 stained in a dotted manner can be seen in the region where PGCs are considered to start differentiating as a cluster of cells. At Late Bud/Early Head Fold stage, some cells considered to be migrating from the initial cluster are stained as well as cells in the cluster. At E8.5 and E9.5, a group of cells considered to be the migrating PGCs are very specifically stained.

- 20 From these results, it is concluded that GCR1 is a gene which is upregulated during the process of lineage specification and germ cell competence, and subsequently of PGCs, when GCR2 is turned on after GCR1 to fix the PGC fate.

- Accordingly, expression of GCR1 may be detected in a method of detecting lineage specification, and/or pluripotency, such as germ cell competence. Similarly,
- 25 expression of GCR2 may be detected to detect commitment to cell fate, for example, commitment to fate as a primordial germ cell.

Example 5. Expression of Fragilis and Stella During Germ Line Development

Antibodies against Stella and Fragilis are used to detect expression of these genes in early embryos. It is found that each of these genes is expressed in primordial germ cells. In particular, we find that Fragilis is the first gene to mark PGC competent cells at the time of germ cell allocation. Stella is expressed only in the lineage-restricted founder PGCs and thereafter in the germ cell lineage.

Figure 3 shows expression of Fragilis in embryonic stem (ES) cells.

Fragilis is expressed in pluripotent ES and EG cells. During the derivation of EG cells from PGCs, it is found that Fragilis expression re-appears on EG cells. Late PGCs are negative for Fragilis after specification of these cells is completed.

Figure 5 shows expression of Fragilis as detected by whole-mount *in situ* hybridization in E7.2 mouse embryos.

There is strong Fragilis expression at the base of incipient allantois where the founder PGC population differentiates in the E7.25 embryos. Fragilis expression persisted until E7.5, but it was not detected in migrating PGCs at E8.5. Fragilis is first detected in germ cell competent proximal epiblast cells. Fragilis expression can be induced in the epiblast cells when combined with the tissues extraembryonic ectoderm tissues, which is the source of BMP4. In the BMP4 mutant mice, there is no expression of Fragilis, consistent with the absence of PGCs in these embryos (Lawson et al., 1999).

Figure 4 shows expression of Stella in PGCs.

Stella expression which is strong in PGCs is downregulated in EG cells. There is also low level expression of Stella in ES cells. Stella and Fragilis are detectable in ES and EG cells by Northern blot analysis. Stella is first detected at E7.0 in single cells within the distinctive cluster of lineage-restricted PGCs, and thereafter in migrating PGCs and subsequently when they enter the gonads. **Figure 7** shows Stella expression in PGCs in

the process of migration into the gonads in E9.0 embryos. Stella is the only gene so far known to be a definitive marker for the founder population of PGCs.

Figure 6 shows expression of Stella as detected by whole-mount *in situ* hybridization in E7.2 mouse embryos.

5 **Figure 8.** Expression of Fragilis and Stella in single cells detected by PCR analysis of single cell cDNAs. Note that there are more single cells showing expression of Fragilis compared to those showing expression of Stella. Only cells with the highest levels of Fragilis expression are found to express Stella and acquire the germ cell fate. Cells that express Stella were found not to show expression of Hoxb1. Cells that express
10 lower levels of Fragilis and no Stella become somatic cells and show expression of Hoxb1. The founder population of PGCs also show high levels of Tnap. Both the founder PGCs and the somatic cells show expression of Oct4, T(Brachyury), and Fgf8.

Example 6. Expression of Fragilis and Stella in Individual Cells

Intracellular localisation of Stella and Fragilis is also determined. Fragilis
15 localised to a single cytoplasmic spot at the Golgi apparatus, as well as in the plasma membrane. Stella comprises a putative nuclear localisation signal and nuclear export signal, and is localised in both the cytoplasm and nucleus.

Fragilis is observed in the Golgi apparatus as well as in the plasma membrane of PGCs. The cell surface localization of Fragilis is expected as a member of the interferon inducible gene family [Deblandre, 1995]. Expression of Fragilis in the proximal rim of
20 the epiblast marks the onset of germ cell competence. *Fragilis* has an IFN response element upstream of its exon 1, so it is very likely to be induced by IFN after initial priming by BMP4 of the proximal epiblast cells. These IFN inducible proteins can form a multimeric complex with other proteins such as TAPA1, which is capable of transduction
25 of antiproliferative signals, which may be why the cell cycle time in founder PGCs increases from 6 to 16hr, while the somatic cells continue to divide rapidly.

Stella, which has the putative nuclear localization signal and a nuclear export signal, was observed in both the cytoplasm and the nucleus. The onset of *Stella* is followed by the loss of *Fragilis* expression by E8.5. Therefore, *Fragilis* expression marks the onset of germ cell competence and *Stella* expression marks the end of this

5 specification process. Expression of *Stella* in the founder PGCs marks an escape from the somatic cell fate and consistent with their pluripotent state. These studies indicate that specific set of genes are required to impose a germ line fate on cells that may otherwise become somatic cells. *Stella*, with its potential to shuttle between the nucleus and cytoplasm, could have a role in transcriptional and translational regulation, since many

10 organisms possess elaborate transcriptional mechanisms to prevent germ cells from becoming somatic cells. Expression of *Stella* in the oocyte and preimplantation embryos indicates that it has a wider role in totipotency and pluripotency.

Example 7. The Link Between *Fragilis* and *Stella*

Only some of the cells that express *Fragilis*, ended up showing expression of

15 *Stella*. Only those cells with the highest levels of *Fragilis* expression become PGCs and began to express *Stella*. Furthermore, *Stella* positive PGCs never show expression of *Hoxb1*. More importantly, only somatic cells with lower levels of *Fragilis* expression, show *Hoxb1* expression. Furthermore, only the somatic cells show expression of two other homeobox-containing genes, *Lim1* and *Evx-1*. Therefore lack of expression of

20 *Hoxb1*, *Evx-1* and *Lim1*, appears to be important for the specification of germ cell fate.

Fig 8a and 8b show expression of various genes in single cell PGCs and somatic cells by PCR analysis.

Our experiments also show that *Oct4* is not a definitive marker of PGC,

Previously, *Oct4* expression is demonstrated in totipotent and pluripotent cells [Nichols, 199, Pesce, 1998; Yeom, 1996]. However, we find that *Oct4* is expressed to the same

25 extent in all PGCs and somatic cells. We do however find expression of *T* (*Brachyuri*) and *Fgf 8* in PGCs indicating that PGCs are recruited from amongst embryonic cells that are initially destined to become mesodermal cells.

Example 8 PGC Specification

The founder PGCs and their somatic neighbours share common origin from the proximal epiblast cells. By analysing the founder PGC and the somatic neighbour, a systematic screen for critical genes for the specification of germ cell fate has been

5 established. Fragilis is an interferon (IFN) inducible gene that can promote germ cell competence and homotypic association to demarcate putative germ cells from their somatic neighbours, and such an example may apply to other situation during development. Expression of Stella occurs in cells with high expression of Fragilis. Fragilis is no longer required once germ cell specification is complete, but Stella

10 expression continues in the germ cell lineage. Stella may also be important throughout in the totipotent/pluripotent cells since it is also expressed in oocytes and early preimplantation development embryos.

Example 9 Germ Line and Pluripotent Stem Cells

PGCs can be used to derive pluripotent embryonic germ (EG) cells. However,

15 unlike EG cells, PGCs do not participate in development if introduced into blastocysts. They either cannot respond to signalling molecules, or that they are transcriptionally repressed. PGCs once specified do not express Fragilis on their cell surface. However, EG cells clearly show expression of Fragilis on their cell surface as do ES cells. Both EG and ES cells express Stella as judged by Northern analysis, although Stella is expressed at a

20 lower level in ES and EG cells than in PGCs. Fragilis and Stella therefore have a role in pluripotent stem cells. These genes are therefore markers of these pluripotent stem cells, where they may also have a role in conferring pluripotency on these stem cells.

Example 10 Proposed Roles of Fragilis and Stella in PGC Specification

Fragilis as a typical IFN-inducible cell surface protein, probably shares certain

25 properties common to all of these family members (Deblandre, G. A. et al. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. *J. Biol. Chem.* 270, 23860–23866 (1995); Evans, S. S., Collea, R. P., Leasure, J. A. & Lee, D. B. IFN- α induces homotypic adhesion and Leu-13 expression in

human B lymphoid cells. *J. Immunol.* 150, 736–747 (1993); Evans, S. S., Lee, D. B., Han, T., Tomasi, T. B. & Evans, R. L. Monoclonal antibody to the interferoninducible protein Leu-13 triggers aggregation and inhibits proliferation of leukemic B cells. *Blood* 76, 2583–2593 (1990)).

- 5 The acute but transient expression of fragilis is itself consistent with the kinetics of IFN-inducible genes that can increase by up to 40-fold within 1 h, and decline quickly after IFN withdrawal (Friedman, R. L., Manly, S. P., McMahon, M., Kerr, I. M. & Stark, G. R. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. *Cell* 38, 745–755 (1984)). This Fragilis positive assembly of
- 10 cells could correspond to about 100 TNAP positive cells (Lawson, K. A. & Hage, W. J. Clonal analysis of the origin of primordial germ cells in the mouse. *Ciba Found. Symp.* 182, 68–84 (1994); Ginsburg, M., Snow, M. H. & McLaren, A. Primordial germ cells in the mouse embryo during gastrulation. *Development* 110, 521–528 (1990)), which is larger than the number of stella positive cells.
- 15 According to our estimates, the stella positive cluster in the 129/SvEv mouse strain consists of approximately 36–43 cells, which is close to the expected 45 nascent PGCs. The fragilis positive cells probably form a community of cells through homotypic adhesion (Evans, S. S., Collea, R. P., Leasure, J. A. & Lee, D. B. IFN- α induces
- 20 homotypic adhesion and Leu-13 expression in human B lymphoid cells. *J. Immunol.* 150, 736–747 (1993); Evans, S. S., Lee, D. B., Han, T., Tomasi, T. B. & Evans, R. L. Monoclonal antibody to the interferoninducible protein Leu-13 triggers aggregation and inhibits proliferation of leukemic B cells. *Blood* 76, 2583–2593 (1990)), from which the founder PGCs are recruited, thus demarcating them from most of the cells destined for somatic tissues. These IFN-inducible cell surface proteins are capable of transduction of
- 25 antiproliferative signals (Deblande, G. A. et al. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. *J. Biol. Chem.* 270, 23860–23866 (1995)), which is a probable mechanism by which the cell cycle time in the nascent PGCs increases from 6 to 16 h, while the somatic cells continue to divide rapidly.

The induction of *fragilis* in epiblast cells may not by itself be sufficient for the expression of *stella*, as shown by our in vitro studies—induction may require a specific signal thought to be within the niche, for PGC specification in vivo (Lawson, K. A. et al. *Bmp4* is required for the generation of primordial germ cells in the mouse embryo. *Genes Dev.* 13, 424–436 (1999); McLaren, A. Signaling for germ cells. *Genes Dev.* 13, 373–376 (1999)). This signal could be a specific ligand that binds to *fragilis* during the specification of germ cell fate. Once nascent PGCs are established, expression of *fragilis* is diminished by E8.0, thus freeing the PGCs from homotypic adhesion for their migration into the genital ridge (Wylie, C. Germ cells. *Cell* 96, 165–174 (1999); Gomperts, M., Garcia-Castro, M., Wylie, C. & Heasman, J. Interactions between primordial germ cells play a role in their migration in mouse embryos. *Development* 120, 135–141 (1994)). *fragilis* must have other functions, as it is apparently expressed elsewhere in developing embryos. In this context, we also note *fragilis* expression in pluripotent ES and embryonic germ cells (data not shown), where it may have a role in the propagation of the pluripotent state.

The role of *stella* may in part be regulated by its potential to shuttle between the nucleus and cytoplasm. We have observed, for example, that overexpression of *stella* in somatic cells causes the protein to be retained in the cytoplasm and not in the nucleus, as is predominantly the case in PGCs (data not shown). A particularly critical event involved in the specification of PGCs is repression of the region-specific homeobox genes, by which nascent PGCs escape from the somatic cell fate. As the expression of *stella* is most intimately connected with the generation of PGCs, this gene is a chief candidate for either initiating or maintaining repression of Hox genes in PGCs. The detection of *stella* in the oocyte and through pre-implantation development (B. Payer et al., unpublished data; Sato, M. et al. Identification of PGC7, a new gene expressed specifically in preimplantation embryos and germ cells. *Mech. Dev.* 113, 91–94 (2002)) suggests that it may serve a critical role during all the phases of totipotent/pluripotent states in mice.

Example 11. *Fragilis* 2, *Fragilis* 3, *Fragilis* 4 and *Fragilis* 5

Specification of primordial germ cells in mice depends on instructive signalling events, which act first to confer germ cell competence on epiblast cells, and second, to

impose a germ cell fate upon competent precursors. *fragilis*, an interferon-inducible gene coding for a transmembrane protein, is the first gene to be implicated in the acquisition of germ cell competence.

In this and the following Examples (Examples 11 to 20), we describe four additional *fragilis*-related genes, *fragilis2-5*, which are clustered within a 70kb region in the vicinity of the *fragilis* locus on Chr 7. These genes exist in a number of mammalian species, which in the human are also clustered on the syntenic region on Chr 11. In the mouse, *fragilis2* and *fragilis3*, which are proximate to *fragilis*, exhibit expression that overlaps with the latter in the region of specification of primordial germ cells. Using single cell analysis, we confirm that all these three *fragilis*-related genes are predominant in nascent primordial germ cells, as well as in gonadal germ cells.

The Fragilis family of interferon-inducible genes is tightly associated with germ cell specification in mice. Furthermore, its evolutionary conservation suggests that it probably plays a critical role in all mammals. Detailed analysis of these genes may also elucidate the role of interferons as signalling molecular during development.

Example 12. Background to Examples

Germ line determination in the mouse is thought to occur through instructive signalling in the gastrulating post-implantation embryo [1, 2]. First, proximal epiblast cells acquire germ cell competence at E6.5, partly in response to extraembryonic ectoderm-derived signalling molecules. A subset of these competent cells then acquire a primordial germ cell (PGC) fate and a population of approximately 45 founder germ cells are detected in the posterior proximal region of the embryo at the base of the incipient allantoic bud on E 7.5 [1, 2]. The secreted signalling molecules, BMP4, BMP8b and BMP2 as well as components of the BMP signal transduction pathway, including Smad1 and Smad5, appear to be involved in the specification of PGCs [3-7]. However, *in vitro* culture studies and analysis of *BMP4*-deficient mice suggest that an additional signal may also be required for the acquisition of PGC fate, but its identity is yet unknown [2, 3].

We have identified *fragilis*, a putative interferon-inducible gene, which codes for a transmembrane protein that is apparently associated with the acquisition of germ cell competence by epiblast cells [8]. Extraembryonic ectoderm is able to induce *fragilis* expression in epiblast tissue, and BMP4 is required for this induction [8]. *fragilis* is expressed in proximal epiblast at E6.5, the region in which PGC-competent cells reside according to clonal analysis [1]. As these proximal cells move to the posterior proximal region during gastrulation, *fragilis* expression increases within a community of cells at the base of the incipient allantoic bud. Cells with the highest expression of *fragilis* initiate the germ cell-characteristic expression of *TNAP* and *stella/PGC-7* [8, 9, 10]. These nascent PGCs with high expression of *fragilis* also show repression of *Hox* genes, including *Hoxb1* in nascent PGCs [8].

In view of the strong association of *fragilis* with PGC specification, we have started to investigate further how this gene may be regulated and what precise function it serves during germ cell development. Towards this objective, we now report that *fragilis* belongs to a novel murine gene family, comprising five members, which code for five highly similar transmembrane proteins. More importantly, the genes are clustered within a 70kb genomic region. As we found several homologues of the Fragilis family in human, cow and rat, they seem to be evolutionarily conserved amongst mammalian species. Most if not all homologous genes have been reported to be responsive to interferon signalling, which is in agreement with the presence of conserved interferon stimutable response elements (ISREs) within at least the murine and human loci. Furthermore, our in situ hybridisation and single cell expression analysis reveal that the two members located close to *fragilis*, *fragilis2* and *fragilis3*, are also expressed in nascent PGCs, although their overall expression pattern in post-implantation embryos in other respects is distinct. Studies on the Fragilis family of genes could therefore be crucial for our understanding of PGC specification, especially since their homologues have been implicated in mediating homotypic cell adhesion and lengthening of the cell cycle time [14, 15]. These studies may also show how interferons act as signalling molecules, which has hitherto not been considered in the context of embryonic development.

Example 13. Materials and Methods: Database searches and animals

Ensembl and NCBI genome browsers are used for data retrieval.

Embryos and genital ridges used for in situ hybridisation experiments came from 129x129 or F1xGoF1 mothers, respectively. Embryos and genital ridges used for single
 5 cell analysis came from 129xSvEv or Oct4GFP(129)xMF1 mothers, respectively. The day of the vaginal plug was designated as E0.5. Embryos were staged according to Downs and Davies [22].

Example 14. Materials and Methods: In situ hybridisation

3'-fragments of *fragilis* and *fragilis2-5* cDNAs were PCR amplified using the
 10 primers described below, and cloned into pGEMT vector (Promega). DIG-labelled antisense RNA probes were synthesized using DIG RNA labelling kit (Sp6/T7; Roche). In situ hybridisation on embryos and urogenital ridges was performed as described [23, 24]. Hybridisation was carried out using 1µg/ml DIG-labelled RNA probe in hybridisation buffer (50% formamide, 1.3x SSC (pH 5), 5mM EDTA (pH 8), 50µg/ml
 15 yeast RNA, 0.2% Tween-20, 0.5% CHAPS, 100µg/ml heparin in DEPC treated H₂O) at 70°C over night. Hybridised probe was detected using alkaline phosphatase conjugated anti-DIG Fab fragments (Roche) and BM Purple alkaline phosphatase substrate (Roche).

Example 15. Materials and Methods: Preparation, PCR and Southern blot analysis of single cell cDNAs

20 Early bud stage embryos (E 7.5) and genital ridges (E 11.5) were isolated in DMEM/10% fetal calf serum/25mM HEPES (pH 7.4). Fragments bearing primordial and gonadal germ cells, respectively, were dissected out and dissociated into single cells. The latter were picked using mouth pipettes and their cDNAs were amplified as described previously [25]. The following primers were used in order to PCR amplify *stella* cDNA
 25 and 3'-fragments of *fragilis* and *fragilis2-5* cDNAs (25 cycles of amplification): *stella*: 5'CTCACAGCTTGAGGCTTCTAA3', 5'GCGATTCAGATGTCTCTGCAC3', *fragilis*: 5'GTTATCACCATTGTTAGTGTCATC3', 5'AATGAGTGTTACACCTGCGTG3';

fragilis3: 5'GATCTTCAGCATCCTTATGGTC3',

5'GAAGGTAACATTTGCATACGCG3'; *fragilis2*:

5'CCTTCCTTATTCTCACTCTG3', 5'GTTGCAAGACATCTCACATC3'; *fragilis4*:

5'AACTTGGAGGCTGCAAGGCAG3', 5'CTCGGAACCTTAGTTATAGTC3';

5 *fragilis5*: 5'TGCTCTGGTCATCTCCCTCA3', 5'CAGGATAAGGGGCAACTCTG3'.

PCR products were run on 1.5% agarose/TBE electrophoresis gels. For Southernblot analysis, single cell cDNAs were blotted onto Hybond-N+ membranes (Amersham) and probed with ³²αP dCTP-labelled DNA probes comprising the 3' regions of *fragilis*,

fragilis2 and *fragilis3* cDNAs and full length *stella* cDNA. *GAPDH* was used as loading

10 control. Blotting signal was detected using a Fuji film FLA 5000 scanner. Signal strength was quantified in relation to *GAPDH* signal, whereby relative gene expression was

calculated as ratio of gene signal to *GAPDH* signal and this ratio was subsequently normalized by division through the highest hybridisation signal per blot. For dotblot

analysis, full length *fragilis* cDNAs were blotted and probed with ³²αP dCTP-labelled 3'

15 probes.

Example 16. The Fragilis gene family

Using the cDNA sequence of *fragilis* as a template to search the ensembl genome browser (www.ensembl.org), we identified eight mouse genes with moderate to high

DNA sequence similarity to *fragilis* (45-74%). ESTs from a variety of embryonic and

20 adult tissues have been reported for five of these genes, of which four possess a two-exon structure similar to *fragilis*. Analysis of the genomic location of the latter revealed that

the four genes cluster around the *fragilis* locus within a 70kb region on the distal tip of

mouse Chr 7 (F5). We therefore named the four novel genes *fragilis2-5*, reflecting their genomic location, similarity to *fragilis* and germ cell associated expression pattern (see

25 below; Figure 9). The four remaining putative genes that we detected have few or mostly no reported ESTs and are coded by a single exon unlike *fragilis*. We therefore consider them to be pseudogenes.

To determine whether the Fragilis genes are evolutionary conserved, we have identified four homologues of mouse Fragilis in the human genome on Chr 11 (p15.5), a

30 region which is indeed syntenic to the Fragilis family locus on mouse Chr 7 (Figure 9).

Three of these genes, *Ifitm1* (9-27), *Ifitm2* (1-8D) and *Ifitm3* (1-8U), share 58-65% similarity to the fragilis gene cluster and are located within an 18kb genomic stretch [11]. They are responsive to type1/2 interferons and code for interferon induced transmembrane (Ifitm) proteins, involved in antiproliferative signalling and homotypic cell adhesion [12-15]. The fourth gene, *ENSG142056*, a novel gene with two exons, is highly similar to mouse *fragilis4* (83% DNA sequence similarity) and neighbours *Ifitm2*. The human Fragilis family homologues hence form a similar genomic cluster as the five Fragilis genes in the mouse. Phylogenetic tree analysis suggests however, that only two Fragilis genes, *fragilis4* and either *fragilis*, *fragilis2* or *fragilis3*, have been conserved from mouse to human (data not shown). Subsequent gene duplications may therefore have occurred independently in both species. We also identified two Fragilis family-like genes in cow (bovine 1-8U, bovine 9-27) and four genes in rat (*P26376*, *JC1241*, *NP110460*, *AAD48010*). While the rat genes have been annotated as putative interferon inducible, the two bovine genes that are similar to the human Ifitm genes, have been reported to respond to interferon signalling [16,17]. Due to limited mapping information of the cow and rat genomes, we cannot, at this stage, deduce whether these homologous genes are also organised in a cluster. Interferon stimuable response elements (ISREs, GGAAAN(N)GAAAC) within the human Ifitm locus confer the responsiveness of the three human Ifitm genes to interferons [11, 18]. Similar ISRE consensus sequences are also found within the Fragilis family cluster in the mouse, associated in particular with *fragilis*, *fragilis 2* and *fragilis5* (Figure 9).

The murine family of *fragilis* and related genes code for five highly similar transcripts of 104 to 144 amino acids, each containing two predicted transmembrane domains (Figure 10). The sequence similarity to human, cow and rat *fragilis*-like genes is equally high (overall 68% amino acid similarity). It should be noted, that the first transmembrane domain as well as the following stretch to the beginning of the second transmembrane domain constitute the regions of highest intra- and inter-species conservation.

Example 17. *fragilis*, *fragilis2* and *fragilis3* are expressed during early post-implantation development

We analysed the expression pattern of the five Fragilis family genes by whole mount *in situ* hybridisation using probes that span the 3' region (150-200bp) of the corresponding mRNAs. These probes show no significant cross-hybridization between members of the Fragilis family as judged by dotblot analysis (data not shown). As reported, we saw expression of *fragilis* restricted to the epiblast at E5.5 and E6.5. More importantly, around E7.5, expression of *fragilis* is intense within a population of cells at the base of the allantois in the region where PGC specification occurs (Figure 11a-c) [8]. *fragilis2* and *fragilis3* are also expressed within the epiblast of E5.5 embryos (Figure 11g, data not shown). While expression of *fragilis2* is thereafter significantly downregulated, *fragilis3* remains expressed at a similar level in the embryonic tissues. At E7.5, *fragilis2* is detected in the posterior mesoderm, while *fragilis3* expression is seen throughout the epiblast. More significantly, like *fragilis*, both *fragilis2* and *fragilis3* show high expression in the region where the cluster of nascent PGCs originates (Figure 11 i/i',n/n'). Thus, these three members of the Fragilis family show significant expression at the time and site of PGC specification.

At E8.5, *fragilis* expression is seen in cells at the base and within the proximal third of the allantois (Figure 11d). Additionally, a signal is detected in the latero-anterior aspects of the developing brain (Figure 11e). At this stage, *fragilis2* is expressed in the mesoderm in the caudal half of the embryo (Figure 11j,k), whereas *fragilis3* appears present throughout the entire embryo with the exception of the developing heart (Figure 11p-r). It is noteworthy, that expression seems significantly stronger in single cells at the base and within the proximal third of the allantois at this stage (Figure 11q). At E9.5, when PGCs have started to migrate along the hindgut, *fragilis* signal is seen in a population of cells located at the beginning of the invaginated hindgut. In addition, the signal appears enhanced in the pharyngeal arches (Figure 11f). At this stage, *fragilis2* expression appears restricted to the tailbud, the mesoderm caudal to the 12th somite and the lung primordium (Figure 11l).

In contrast to the first three members of the family, neither *fragilis4* nor *fragilis5* showed expression at early post-implantation stages (E7.0-E8.5, data not shown).

Consequently, only the three genes at the centre of the family cluster, that is *fragilis*, *fragilis2* and *fragilis3* are expressed in the embryo between E5.5 and E9.5. While their expression pattern is distinct, there is a striking overlap within the region where founder germ cells are located. This suggests that the three neighbouring genes, *fragilis*, *fragilis2* and *fragilis3*, may share regulatory elements that are likely to be present within the cluster. These regulatory elements may also be responsible for the genes' overlapping expression pattern specifically around the region of nascent PGCs.

10 **Example 18. Single cell analysis of *fragilis*, *fragilis2* and *fragilis3* in PGCs and somatic neighbours**

To obtain more precise information on the expression of the new Fragilis family members in the context of germ cell specification, we tested single cell cDNAs from PGCs and surrounding somatic cells sited at the base of the incipient allantoic bud in E7.5 embryos. Both *fragilis2* and *fragilis3* were expressed in nascent PGCs, which show transcription of the germ cell marker *stella/PGC7* (Figure 13a) [8,10]. The two Fragilis family members were also detected in surrounding somatic cells that lack expression of *stella/PGC7* [8]. Importantly, semi-quantitative analysis using Southernblotting showed that *fragilis2* and *fragilis3* are expressed predominantly and at higher levels in nascent PGCs compared to the neighbouring somatic cells (Figure 13b,c). This mimics the pattern seen for *fragilis*, although expression of the latter is more specific to germ cells. Combined with the in situ hybridisation data, these observations further support the notion that certain common control elements may be involved in the upregulated expression of the three Fragilis genes in the founder PGCs.

During the developmental stages directly subsequent to PGC specification, all three Fragilis family genes are expressed in a population of cells associated with the allantois and in a location where premigrating PGCs are thought to reside (Figure 11d,k,q). The precise gene expression during migration of PGCs is not clear at this stage from our analysis. However, using in situ hybridisation and PCR analysis of cDNAs from single cells within the genital ridge, we found clear expression of *fragilis*, *fragilis2* and

fragilis3 in the gonadal germ cells at E11.5-12.5 (Figure 14). While *fragilis3* expression extends to the mesonephros, *fragilis* and *fragilis2* signal was restricted to the genital ridge. A punctuate staining pattern was seen for *fragilis*, mimicking the germ cell restricted expression of *stella/PGC7* (Figure 14b). This pattern in addition to the PCR analysis suggests that *fragilis* is expressed predominantly if not solely in germ cells at E11.5. As was the case in earlier embryos, neither *fragilis4* nor *fragilis5* were detected in gonadal germ cells (data not shown).

Example 19. Discussion

In this study we describe the identification of the murine Fragilis gene family, which appears to be conserved amongst mammalian species, and whose members code for five highly similar transmembrane proteins. Three members of the Fragilis family, *fragilis*, *fragilis2* and *fragilis3*, exhibit expression, which is associated with germ cell specification and development. Located at the cell membrane, the Fragilis proteins may be crucial for mediating interactions amongst germ cells and their surrounding neighbours. While the three genes are expressed earlier at E5.5 and thereafter to a varying extent, they all show upregulation of expression within nascent PGCs. It is likely that a cis control element exists within the locus that is required for this expression, which continues within gonadal PGCs. Future studies will elucidate where these control elements are located and how they regulate expression of the *fragilis*-related genes.

Although the five Fragilis family members are clustered within a small genomic region, it appears that neither *fragilis4* or *fragilis5* show expression in early embryos or embryonic germ cells. It is striking that these two members are located at the periphery of the cluster in contrast to the centrally located *fragilis*, *fragilis2* and *fragilis3* genes. This lack of expression may be due to the presence of boundary elements, which might restrict the action of control elements to genes present within the centre of the cluster. Since sequence comparison suggests that gene duplications may have occurred independently in the two species, it appears that a certain evolutionary constrain may exist on duplication and maintenance of the duplicated genes within immediate neighbourhood. Since the four human homologues of the Fragilis family in the syntenic region are also arranged in a

genomic cluster and are highly similar to the family genes, it is tempting to suggest that they may also serve similar functions as in the mouse.

The presence of several interferon stimuable response element (ISRE) consensus sequences within the Fragilis locus, together with the similarity of the genes to their
5 interferon-inducible human and bovine counterparts, suggest very strongly that *fragilis*
and the *fragilis*-related genes are responsive to interferons. Indeed, the ISRE tandem
repeat present in the 5' flanking region of human *Ifitm1*, *Ifitm2* and *Ifitm3* genes is also
present in the 5' flanking region of *fragilis* exon 1 [11]. Interferons, as secreted signalling
molecules, have so far been implicated mainly in the process of immune response, the
10 inhibition of cellular growth and the control of apoptosis [19]. Although interferons are
expressed in the post-implantation embryo, their role during development has not been
addressed in detail [20, 21]. Our studies have pointed to a possible involvement of
interferons in germ cell development. Future work will determine whether the Fragilis
genes respond to interferon signals in all or some instances where the genes are
15 expressed, which we expect in view of the presence of conserved ISRE elements in the
mouse and human loci.

Example 20. Conclusion

We have identified the Fragilis family of interferon inducible genes, which code
for transmembrane proteins. The five members are arranged in a cluster within a genomic
20 region of 70kb in the mouse that also contains ISRE elements. The centrally located
fragilis, *fragilis2* and *fragilis3* genes are of particular interest, because they are expressed
in the region where germ cell specification occurs. The family is evolutionary conserved
amongst mammalian species where it may serve similar functions. Detailed studies of the
Fragilis family may also show what role interferons have in embryonic development.

25 Example 21. Stella is a maternal effect gene required for normal early development in mice

In this and the following Examples (Examples 21 to 25), we have investigated the
effects of a targeted mutation of *stella* in mice. Maternal inheritance in mammalian

oocytes includes proteins important for totipotency and epigenetic modifications¹, as well as factors crucial for early development, which are transcribed from so called maternal effect genes²⁻⁷.

5 Amongst these maternally inherited proteins is Stella, which is also expressed in preimplantation embryos, primordial germ cells, and pluripotent cells^{8,9}. We show that while matings between heterozygous animals resulted in the birth of apparently normal *stella*-null offspring, *stella*-deficient females showed severely reduced fertility, which is due to a lack of maternally inherited Stella in their oocytes.

10 *Stella* is a maternal effect gene, as the phenotypic effect on embryonic development is a consequence of the maternal *stella* mutant genotype. Indeed, we demonstrate that embryos lacking Stella-protein are compromised in preimplantation development and rarely reach the blastocyst stage. Furthermore, we show that *STELLA* that is expressed in human oocytes¹⁰ is also expressed in human pluripotent cells and in germ cell tumours. Interestingly, human chromosome 12p, which harbours *STELLA* is
15 consistently overrepresented in these tumours¹¹. These findings suggest a similar role for *STELLA* during early human development as in mice and a potential involvement in germ cell tumours.

The aim of this study was to determine the role of *stella* by loss of function analysis in mice. In our previous work, we have shown that expression of *stella* (also
20 called PGC7) is activated during the process of germ cell specification at E7.25 specifically in the founder population of lineage restricted primordial germ cells (PGCs)^{8,9}. Thereafter it is expressed in the germ line until about E15.5 in male and E13.5 in female gonads. Expression of *stella* resumes in the immature oocytes in newborn ovaries, and it is subsequently detected in maturing oocytes and in preimplantation
25 embryos (Figure 15a-l)⁸. Soon after the formation of the zygote, Stella accumulates in the pronuclei, although it is also detected in the cytoplasm (Figure 15d-f). Both cytoplasmic and nuclear staining continues during cleavage stages until the blastocyst stage, after which Stella is downregulated (Figure 15g-l and data not shown)⁸, until its re-appearance in the nascent PGCs^{8,9}.

Example 22. Materials and Methods

Immunofluorescence

Embryos were fixed in 4% paraformaldehyde for 15 minutes, washed 3 times with PBS and permeabilised in AB-buffer (1% Triton-X100, 0.2% SDS, 10 mg/ml BSA in PBS), which was also used for the following antibody incubations and washes. They were then incubated in primary antibody (anti-Stella⁹ 1:200, anti-PGC7⁸ 1:2000) overnight at 4°C, washed 3 times and incubated with secondary antibody for 1-2 hours at room-temperature (Alexa 564, Molecular probes, 1:500). After 3 further washes in AB-buffer, embryos were rinsed once in PBS and incubated at 37°C with 0.1 mg/ml Rnase A (Roche) in PBS for 30 minutes. Finally embryos were incubated for 10 minutes in PBS with propidium iodide (2 µg/ml) and mounted on slides in Vectashield (Vector Laboratories) mounting medium, which also contained propidium iodide.

For E11.5 PGC-stainings, genital ridges were washed in PBS, treated for 10 minutes at 37°C with Trypsin/EDTA (Gibco), diluted in PBS and dissociated into a cell suspension. Cells were allowed to settle down on poly-L-lysine treated slides and fixed with 3% formaldehyde for 15 minutes. After permeabilisation with 0.2% Triton X-100 in PBS and 3 washes in PBS cells were blocked with 3% BSA in PBS (also used for subsequent washes and antibody dilutions) for 40 minutes and incubated with primary antibodies (anti-Stella 1:100, anti-SSEA1 (=TG1), P. Beverley 1:2) overnight at 4°C. Then the cells were washed and incubated with secondary antibodies (Alexa 564, Alexa 488, Molecular probes, 1:500) for 1.5 hours. After washing, Rnase (0.1 mg/ml) treatment was done for 1 hour at room temperature and the cells were mounted with Vectashield containing Toto-3 (Molecular probes, 1:1000).

Immunofluorescence was visualized on a BioRad Radiance 2000 confocal microscope.

Identification of stella-homologues

Human *STELLA* was identified by blasting the mouse Stella protein sequence against the translated human genome sequence using the Ensembl server (<http://www.ensembl.org>). The only hit showing the same intron-exon structure as the

mouse gene is located on the syntenic region (Figure 15*m,n*) and was therefore considered to be the human orthologue (hits without introns were considered as pseudogenes). Three IMAGE-EST clones (Genbank IDs: AA927342, AI066520, AA564230; UniGene cluster Hs.131358), which aligned to the genomic region, were fully sequenced by us to confirm the predicted sequence.

The putative rat-*stella* sequence was mapped as above and deduced from the alignment of the mouse cDNA sequence with the syntenic rat genome sequence.

RT-PCR analysis of human tissues

1 µg total RNA of each human tissue (source: Ambion and see acknowledgements) was reverse transcribed into 1st strand cDNA with Superscript II reverse transcriptase (Gibco) for 1 hour at 37°C. 1 µl of this cDNA was amplified by a 30 cycle PCR-reaction using primers for human *STELLA* (5'-CAATTTGAGGCTCTGTCATCAG-3', 5'-TTCATCTCACTGACTTTGGGC-3') or ribosomal protein *L32* (5'-AGTTCCTGGTCCACAACGTC-3', 5'-TGCACATGAGCTGCCTACTC-3').

ES-cell manipulation and knockout verification

The targeting construct consisted of 1.5 kb of upstream and 4.1 kb of downstream genomic sequence flanking the second exon of *stella*. The 5' arm terminated after the first 32 bp of exon 2, which was fused to an IRES lacZ reporter, followed by a promoted neo selectable marker. The construct was linearized and electroporated into CCB mouse embryonic stem (ES) cells which were placed under selection. Individual G418-resistant clones were picked and screened for correct integration of the targeting construct by PCR using a vector primer and a primer external to the 5' arm. 288 clones were screened of which two exhibited the expected size bands in the PCR. Homologous recombination was also confirmed by Southern blot using 5', 3' and neo-probes on NcoI and EcoRI digested genomic DNA. The correctly targeted ES-cell clone F4 was injected into MF1 and C57BL/6 blastocysts to produce chimeric mice. Germline transmission was achieved by breeding the male chimeras with 129Sv/Ev females. All analysis was done on the inbred 129Sv/Ev background. To confirm that the *stella* gene was correctly inactivated, mice were genotyped by Southern blot as above (Figure 16*b*). Furthermore we performed RT-

PCR (same protocol as for human tissues – see above) on testis and ovary RNA of wt, heterozygous and homozygous mice (Figure 16c), using exon 2-specific primers (5'-AGACGTCCTACAACCAGAAAC-3', 5'-CCGAACAAGTCTTCTCATCTT-3').

Counting of primordial germ cells

- 5 Embryos of *stella*-heterozygous intercrosses were dissected out at E8.5, fixed with 4% paraformaldehyde and stained for TNAP-positive PGCs with α -naphthyl phosphate / fast red TR solution (Sigma) as previously described^{20,26}. The posterior parts of the embryos were flattened under coverslips and used for counting PGCs, while the anterior parts were used for genotyping by PCR.

10 *Histology*

- Testes and ovaries from adult mice were fixed in Bouin's fixative at 4°C overnight and washed thoroughly in 80% ethanol. After dehydration through an ethanol series they were transferred into xylene and embedded in Paraplast Plus wax (Sigma). 8 μ m sections were cut, rehydrated and stained with Ehrlich's Haematoxylin (BDH) and 1% eosin
15 (Sigma). After dehydration, slides were mounted with DPX (BDH).

Matings and in vitro culture

- All studies for the assessment of fertility and embryonic development were done using natural matings. Mice were kept on a constant light/dark cycle and mating was assumed to have happened in the middle of the dark period before a vaginal plug was
20 detected (E0.5 = midday on day of plug). Embryos were collected by flushing oviducts/uteri at the time of the observed stages (E0.5 - E3.5) or at E1.5, if they were cultured. Culturing was done under 5% CO₂ in KSOM medium.
Work on animals was performed under Home Office project licences PPL80/1280 and PPL80/1706.

25 *Generation of stella-GFP mice*

Using the *stella*-cDNA as a probe, we screened a gridded genomic 129 pBeloBAC library (Genome Systems St Louis, MO) to identify a clone harbouring the *stella* locus.

We subcloned 11.5 kb of genomic sequence including about 8.5 kb upstream sequence and exon 1, intron 1 and the start of exon 2 and fused it in frame to *eGFP* (Clontech) and a SV40-polyadenylation signal. This sequence was then injected into pronuclei of B6CBA F2 zygotes, to generate transgenic mice. The transgene was maintained on the same genetic background and the onset of expression of the paternal allele was observed by mating *stella-GFP* transgenic males with non-transgenic females.

The cDNAs of the Stella homologues mentioned in this study have the following GenBank accession numbers: mouse Stella (AY082485), rat Stella (BK001414, pending), human STELLA (AY317075, pending).

10 **Example 23. Stella Homologues**

We have now identified *stella* homologues in the rat and human genomes, which show the same exon-intron structure, and are located within the syntenic chromosomal regions (see Figure 15*m,n*). The mouse gene is in position F2 of chromosome 6, the rat gene on q42 of chromosome 4 and the human gene on p13.31 of chromosome 12. Only one expressed-sequence tag (EST) (BI289609, aorta pool) was found in the rat, while several human ESTs mainly from germ cell tumour libraries (UniGene cluster Hs.131358) matched the genomic sequence. The full-length amino acid sequences (Figure 15*o*) of the mouse and rat protein showed 70% identity (84% similarity), but the mouse and human proteins shared only 35% identity (53% similarity). While the Stella orthologues of rodents and humans have clearly diverged, conserved sequence stretches are found in the centre and the C-termini of the proteins. The biochemical function of these motifs remains to be discovered, but some of the predicted nuclear localisation and export signals reside within the regions of higher conservation.

Example 24. Expression of Stella

To study the expression of human *STELLA*, we performed RT-PCR analysis on pluripotent cell lines and reproductive organs (Figure 15*p*). We detected *STELLA* in human embryonic stem (ES) cells and embryonic carcinoma (EC) cells, as well as in normal testis and ovary. The strongest expression was found in a testicular germ cell

tumour, which shows characteristics of pluripotency¹¹. Expression of *STELLA* in other tumours and somatic tissues was either very low or undetectable (data not shown). Our findings concur with a recent study¹⁰, where *STELLA* (termed fragment 7.1) was detected in human oocytes and in EC cells, in which it was down-regulated after retinoic acid-induced differentiation. These findings strengthen the hypothesis that *STELLA* might have a similar role in humans as in mice. Furthermore, the short arm of chromosome 12 (12p) on which *STELLA* is located, is consistently overrepresented in testicular germ cell tumours¹¹. *Stella/STELLA* resides within a conserved cluster of genes consisting of *nanog/NANOG*^{12,13} and *gdf3/GDF3*¹⁴ (Figure 15n), which are associated with pluripotency and germ cell tumours. The conserved proximity in mice and humans and the overlapping expression patterns of these genes suggest a possible co-regulation at a transcriptional level¹⁵. Clearly, these findings prompt a careful analysis of the functions of *stella* and its neighbours in mouse and man.

Example 25. Stella Knockout Mice

To begin to address functions of *stella*, we generated *stella* knockout (*stella*^{-/-}) mice (Figure 16). Matings between heterozygous (*stella*^{+/-}) mice on the 129/SvEv background resulted in the birth of 192 pups consisting of 56 (29.2%) wild-type, 81 (42.2%) *stella*^{+/-} and 55 (28.6%) *stella*^{-/-} mice, in the approximate mendelian ratio of 1:2:1. Therefore, *stella*^{-/-} deficient mice are viable and survive at a normal rate.

As *stella* is detected in the founder PGCs, we examined *stella*^{-/-} mice for any effects on development of germ cells. Examination of germ cells at E8.5 in mutant embryos by tissue non specific alkaline phosphatase (TNAP) activity, a marker of PGCs¹⁶, revealed no significant differences in the numbers of PGCs compared to those in wild-type embryos (Figure 17a). Similarly we found no effect on early gonadal PGCs (E11.5) in knockout embryos, detected by the germ cell marker SSEA1¹⁷ (Figure 17b). Furthermore, histological examination of testes and ovaries of adult mice showed no gross abnormalities in the development of gametes in *stella* mutant animals (Fig 3h-m). Indeed *stella*^{-/-} males showed normal fertility when mated with wild-type or heterozygous females. In mutant females, we detected oocytes at all stages of development and we found similar numbers of ovulated oocytes compared to those from control animals

(*stella*^{-/-} 8.6 ± 1.0, n=9; wild-type or *stella*^{+/-} 9.0 ± 0.4, n=19), suggesting that the loss of *stella* has no gross effects on either germ cell determination or development.

Next, we examined if development progressed normally from oocytes of *stella*^{-/-} females that lack maternal inheritance of Stella. Despite the ovulation of normal numbers of Stella-deficient oocytes, female *stella*^{-/-} mice displayed a strongly reduced fertility. When *stella*^{-/-} females were mated with wild-type males, only a low percentage of matings (detected by vaginal plugs) (24%, Figure 18a) resulted in full pregnancy and live young. Those females, which failed to become pregnant mated again after approximately 10 days, which reflects lack of embryo implantation in these females and the consequent resumption of the estrous cycle after a period of pseudopregnancy¹⁸. By contrast, 80% of wild-type females (littermate controls), became pregnant and produced litters following mating (Figure 18a). Furthermore, even those *stella*^{-/-} females that became pregnant, produced considerably smaller litters compared to the wild-type females (Figure 18b). Preliminary results also show reduced fertility in an outbred strain (129SvEv / C57BL/6), although the effect is stronger in inbred 129Sv/Ev mice. This is consistent with previous reports that genetic background can alter the severity of knockout phenotypes¹⁹, including defects in germ cell development^{20,21}. These observations demonstrate that embryos derived from Stella-depleted oocytes are affected in development and that *stella* is a maternal effect gene, because the oocytes were fertilised by normal sperm from wild-type males.

Next we wanted to know, if the Stella protein in preimplantation embryos (Figure 15)⁸ is exclusively maternally inherited and therefore absent in embryos derived from *stella*^{-/-} females, or if *stella* expression commences from the paternal allele after fertilisation by wild-type sperm. For this purpose, we made transgenic mice using a *stella-GFP* reporter transgene (Figure 18c-i). When a *stella-GFP* transgenic male was mated with a non-transgenic female, we detected the transgene expression as early as the 2-cell stage (E1.5, Figure 18e,h), the time when the bulk of embryonic transcription and translation begins²². This indicates that the *stella* gene is transcribed very early during preimplantation development. We confirmed this observation by anti-Stella antibody stainings of E2.5 embryos (Figure 18j-l), which were derived from mating a wild-type male with a *stella*^{-/-} female. Therefore, Stella is clearly made in early embryos produced

by matings between *stella*^{-/-} females and wild-type males. But despite this, the majority of Stella-deficient oocytes did not develop normally to term, demonstrating that the onset of *stella* expression as early as the 2-cell stage from the paternal allele is not sufficient to fully rescue the observed maternal effect phenotype. By contrast, the maternally inherited
5 Stella is sufficient for normal development, as *stella*^{-/-} mice are born from heterozygous females mated with homozygous males at the same frequency as wild-type mice (see above).

We then addressed the question concerning the embryonic stages at which the absence of Stella affects development. As we have so far not obtained any live young
10 from matings between *stella*^{-/-} males and *stella*^{-/-} females, we examined embryos from these matings, and compared it with embryos from matings between wild-type or *stella*^{-/-} males with wild-type or *stella*^{+/-} females (Figure 19). While fertilisation seems to proceed normally in oocytes from *stella*^{-/-} females, the effects of lacking Stella become evident shortly thereafter, with progressively fewer embryos exhibiting normal development at
15 each time point examined (Figure 19a). The cumulative manifestation of developmental anomalies are starkly obvious at E3.5, when most of the embryos from controls (69%) reach the blastocyst stage, while only 6% of embryos in *stella*^{-/-} mothers do so (Figure 19 a-c). This observation was further supported by examination of similar embryos cultured *in vitro* for 3 days until E4.5, when only 15% of embryos from mutant oocytes reached
20 the blastocyst stage compared to 69% for controls. 49% of mutant embryos were still at the single-cell stage, fragmenting or exhibiting asymmetric or abnormal cleavage. The remainder were found at various stages including 10% at the 2-cell stage and 27% at the morula stage (Fig 5d-f). Since uterine receptivity for blastocyst implantation is restricted to late E3.5 to early E4.5, only those embryos that reach the blastocyst stage by that time
25 can implant^{23,24}. This is consistent with the observation that *stella*^{-/-} females rarely become pregnant and when they do, they produce very small litters. In several cases, *stella*^{-/-} females only become pseudopregnant and resume mating after 10 days, which is indicative of a lack of implanting blastocysts in these females¹⁸.

In conclusion, we demonstrate that the maternal inheritance of Stella is needed for
30 normal embryonic development. Depletion of Stella from the oocytes compromises this process, resulting in a progressive decline in the numbers of blastocysts, fewer implants

and a poor yield of viable young. Stella is a basic protein with a SAP-like domain²⁵ and a splicing factor-like motif and therefore likely to have a role in chromosomal organisation or RNA metabolism. We propose to look for the interacting partners and the biochemical activity of the conserved domains of Stella to elucidate its role in early development.

- 5 Despite a lack of gross abnormalities in germ cell development in *stella*^{-/-} mice, we cannot rule out subtle effects. One possibility is functional redundancy through compensation by *stella*-related genes. There are several *stella*-like sequences in the mouse genome, although these are likely to be pseudogenes (data not shown). *STELLA* is also expressed in human oocytes¹⁰, where it is likely to play a similar role in early development as in
- 10 mice. As the highest expression of *STELLA* is in a human testicular germ cell tumour, this could serve as a diagnostic marker or be of therapeutic value in the future. The conservation of the syntenic chromosomal region harbouring *STELLA*, together with *NANOG* and *GDF3* on chromosome 12p is noteworthy as it is associated with pluripotency, teratocarcinomas and germ cell tumours in humans. The role of likely
- 15 coordinated regulation of all key genes within the region may provide evolutionary insights into aspects of germ cell development and germ cell tumours, as well as on pluripotency and maternal effect genes.

REFERENCES

- 20 Brady, G. and Iscove, N.N. (1993). Construction of cDNA libraries from single cells. *Methods Enzymol.* 225, 611-623.
- Dulac, C. and Axel, R. (1995). A novel family of genes encoding putative pheromone receptors in mammals. *Cell* 83, 195-206.
- Ginsburg, M., Snow, M.H.L., and McLaren, A. (1990). Primordial germ cells in the mouse embryo during gastrulation. *Development* 110, 521-528.
- 25 Downs, K.M., and Davies, T. (1993). Staging of gastrulating mouse embryos by morphological landmarks in the dissecting microscope. *Development* 118, 1255-1266.

- Lawson, K.A., Dunn, N.R., Roelen, B.A.J., Zeinstra, L.M., Davis, A.M., Wright, C.V.E., Korving, J.P.W.F.M., and Hogan, B.L.M. (1999). Bmp4 is required for the generation of primordial germ cells in the mouse embryo. *Genes&Dev.* 13, 424-436.
- Yoem, Y.II., Fuhrmann, G., Ovitt, C.E., Brehm, A., Ohbo, K., Gross, M., Hubner, K., and Scholer, H.R. (1996). Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. *Development* 1996, 881-894.
1. Weismann, A. Das Keimplasma. Eine theorie der Vereburg. *Jenna. Gustav Fischer* (1892).
 2. Eddy, E. M. Germ plasm and the differentiation of the germ cell line. *Int Rev Cytol* 43, 229-80 (1975).
 3. Seydoux, G. & Strome, S. Launching the germline in *Caenorhabditis elegans*: regulation of gene expression in early germ cells. *Development* 126, 3275-83. (1999).
 4. Wylie, C. Germ cells. *Cell* 96, 165-74. (1999).
 5. Lawson, K. A. et al. Bmp4 is required for the generation of primordial germ cells in the mouse embryo. *Genes Dev* 13, 424-36. (1999).
 6. Lawson, K. A. & Hage, W. J. Clonal analysis of the origin of primordial germ cells in the mouse. *Ciba Found Symp* 182, 68-84 (1994).
 7. Tam, P. P. & Zhou, S. X. The allocation of epiblast cells to ectodermal and germ-line lineages is influenced by the position of the cells in the gastrulating mouse embryo. *Dev Biol* 178, 124-32. (1996).
 8. Yoshimizu, T., Obinata, M. & Matsui, Y. Stage-specific tissue and cell interactions play key roles in mouse germ cell specification. *Development* 128, 481-90. (2001).

9. McLaren, A. Signaling for germ cells. *Genes Dev* **13**, 373-6. (1999).
10. Ying, Y., Liu, X. M., Marble, A., Lawson, K. A. & Zhao, G. Q. Requirement of Bmp8b for the generation of primordial germ cells in the mouse. *Mol Endocrinol* **14**, 1053-63. (2000).
- 5 11. Ying, Y., Qi, X. & Zhao, G. Q. Induction of primordial germ cells from murine epiblasts by synergistic action of BMP4 and BMP8B signaling pathways. *Proc Natl Acad Sci U S A* **98**, 7858-7862. (2001).
12. Ying, Y. & Zhao, G. Q. Cooperation of endoderm-derived BMP2 and extraembryonic ectoderm-derived BMP4 in primordial germ cell generation in the
10 mouse. *Dev Biol* **232**, 484-92. (2001).
13. Chiquoine, A. D. The identification, origin and migration of the primordial germ cells in the mouse embryo. *Anat Rec* **118**, 135-146 (1954).
14. Ginsburg, M., Snow, M. H. & McLaren, A. Primordial germ cells in the mouse embryo during gastrulation. *Development* **110**, 521-8. (1990).
- 15 15. MacGregor, G. R., Zambrowicz, B. P. & Soriano, P. Tissue non-specific alkaline phosphatase is expressed in both embryonic and extraembryonic lineages during mouse embryogenesis but is not required for migration of primordial germ cells. *Development* **121**, 1487-96. (1995).
16. Nichols, J. et al. Formation of pluripotent stem cells in the mammalian
20 embryo depends on the POU transcription factor Oct4. *Cell* **95**, 379-91. (1998).
17. Pesce, M., Gross, M. K. & Scholer, H. R. In line with our ancestors: Oct-4 and the mammalian germ. *Bioessays* **20**, 722-32. (1998).
18. Yeom, Y. I. et al. Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. *Development* **122**, 881-94. (1996).

19. Downs, K. M. & Davies, T. Staging of gastrulating mouse embryos by morphological landmarks in the dissecting microscope. *Development* **118**, 1255-66. (1993).
20. Brady, G. & Iscove, N. N. Construction of cDNA libraries from single
5 cells. *Methods Enzymol* **225**, 611-23 (1993).
21. Dulac, C. & Axel, R. A novel family of genes encoding putative pheromone receptors in mammals. *Cell* **83**, 195-206. (1995).
22. Frohman, M. A., Boyle, M. & Martin, G. R. Isolation of the mouse Hox-2.9 gene; analysis of embryonic expression suggests that positional information along the
10 anterior-posterior axis is specified by mesoderm. *Development* **110**, 589-607. (1990).
23. Deblandre, G. A. et al. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. *J Biol Chem* **270**, 23860-6. (1995).
24. Friedman, R. L., Manly, S. P., McMahon, M., Kerr, I. M. & Stark, G. R.
15 Transcriptional and posttranscriptional regulation of interferon- induced gene expression in human cells. *Cell* **38**, 745-55. (1984).
25. Evans, S. S., Collea, R. P., Leasure, J. A. & Lee, D. B. IFN-alpha induces homotypic adhesion and Leu-13 expression in human B lymphoid cells. *J Immunol* **150**, 736-47. (1993).
- 20 26. Evans, S. S., Lee, D. B., Han, T., Tomasi, T. B. & Evans, R. L. Monoclonal antibody to the interferon-inducible protein Leu-13 triggers aggregation and inhibits proliferation of leukemic B cells. *Blood* **76**, 2583-93. (1990).
27. Aravind, L. & Koonin, E. V. SAP - a putative DNA-binding motif involved in chromosomal organization. *Trends Biochem Sci* **25**, 112-4. (2000).

28. Gurdon, J. B., Lemaire, P. & Kato, K. Community effects and related phenomena in development. *Cell* **75**, 831-4. (1993).
29. Reid, L. E. et al. A single DNA response element can confer inducibility by both alpha- and gamma-interferons. *Proc Natl Acad Sci U S A* **86**, 840-4. (1989).
- 5 30. Kita, M. et al. [Expression of cytokines and interferon-related genes in the mouse embryo]. *C R Seances Soc Biol Fil* **188**, 593-600 (1994).
31. Gomperts, M., Garcia-Castro, M., Wylie, C. & Heasman, J. Interactions between primordial germ cells play a role in their migration in mouse embryos. *Development* **120**, 135-41. (1994).
- 10 32. Herrmann, B. G., Labeit, S., Poustka, A., King, T. R. & Lehrach, H. Cloning of the T gene required in mesoderm formation in the mouse. *Nature* **343**, 617-22. (1990).
33. Herrmann, B. G. Expression pattern of the Brachyury gene in whole-mount TWis/TWis mutant embryos. *Development* **113**, 913-17
- 15 34. Crossley, P. H. & Martin, G. R. The mouse Fgf8 gene encodes a family of polypeptides and is expressed in regions that direct outgrowth and patterning in the developing embryo. *Development* **121**, 439-51. (1995).
35. Barnes, J. D., Crosby, J. L., Jones, C. M., Wright, C. V. & Hogan, B. L. Embryonic expression of Lim-1, the mouse homolog of Xenopus Xlim-1, suggests a role
20 in lateral mesoderm differentiation and neurogenesis. *Dev Biol* **161**, 168-78. (1994).
36. Fujii, T. et al. Expression patterns of the murine LIM class homeobox gene lim1 in the developing brain and excretory system. *Dev Dyn* **199**, 73-83. (1994).

37. Bastian, H. & Gruss, P. A murine even-skipped homologue, *Evx 1*, is expressed during early embryogenesis and neurogenesis in a biphasic manner. *Embo J* **9**, 1839-52. (1990).
38. Rogers, M. B., Hosler, B. A. & Gudas, L. J. Specific expression of a retinoic acid-regulated, zinc-finger gene, *Rex- 1*, in preimplantation embryos, trophoblast and spermatocytes. *Development* **113**, 815-24. (1991).
39. Sutton, J. et al. Genesis, a winged helix transcriptional repressor with expression restricted to embryonic stem cells. *J Biol Chem* **271**, 23126-33. (1996).
40. Cox, D. N. et al. A novel class of evolutionarily conserved genes defined by *piwi* are essential for stem cell self-renewal. *Genes Dev* **12**, 3715-27. (1998).
41. Fujiwara, Y. et al. Isolation of a DEAD-family protein gene that encodes a murine homolog of *Drosophila vasa* and its specific expression in germ cell lineage. *Proc Natl Acad Sci U S A* **91**, 12258-62. (1994).
42. Dixon, K. E. Evolutionary aspects of primordial germ cell formation. *Ciba Found Symp* **182**, 92-110 (1994).
43. Mahowald, A. P. Assembly of the *Drosophila* germ plasm. *Int Rev Cytol* **203**, 187-213 (2001).
44. Nieuwkoop, P. D. & Satasurya, L. A. Primordial germ cells in the chordates. *Cambridge University Press, Cambridge, UK* (1979).
45. Johnson, A. D., Bachvarova, R. F., Drum, M. & Masi, T. Expression of *axolotl dazl* mRNA, a marker of germ plasm: widespread maternal mRNA and onset of expression in germ cells approaching the gonad. *Dev Biol* **234**, 402-15. (2001).

46. Johnson, A. D., Bachvarova, R. F., Masi, T. & Drum, M. Expression of *Vasa* and *Daz-like* genes demonstrate that Axolotl primordial germ cells (PGCs) are not predetermined. *Germ cells Cold Spring harbor laboratory*, 61 (2000).
47. Toyooka, Y. et al. Expression and intracellular localization of mouse Vasa-homologue protein during germ cell development. *Mech Dev* **93**, 139-49. (2000).
48. Saitou, M. et al. Occludin-deficient embryonic stem cells can differentiate into polarized epithelial cells bearing tight junctions. *J Cell Biol* **141**, 397-408. (1998).
49. Henrique, D. et al. Expression of a Delta homologue in prospective neurons in the chick. *Nature* **375**, 787-90. (1995).
50. Wilkinson, D. G. & Nieto, M. A. Detection of messenger RNA by in situ hybridization to tissue sections and whole mounts. *Methods Enzymol* **225**, 361-73 (1993).
51. Winnier, G., Blessing, M., Labosky, P. A. & Hogan, B. L. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. *Genes Dev* **9**, 2105-16. (1995).

REFERENCES FOR EXAMPLES 11 TO 20

1. KA Lawson, WJ Hage: **Clonal analysis of the origin of primordial germ cells in the mouse. Germline development.** In *Wiley, Chichester (Ciba Foundation Symposium 182)* 1994, 68-91
2. A McLaren: **Signaling for germ cells.** *Genes Dev* 1999, **13**: 373-376
3. KA Lawson, NR Dunn, BAJ Roelm, LM Zeinstra, AM Davies, CVE Wright, JPWFM Korving, BLM Hogan: ***Bmp4* is required for the generation of primordial germ cells**

- in the mouse embryo. *Genes Dev* 1999, 13: 424-436**
4. Y Ying, XM Lui, A Marble, KA Lawson, GQ Zhao: **Requirement of Bmp8b for the generation of primordial germ cells in the mouse. *Mol Endocrinol* 2000, 14: 1053-1063**
- 5
5. H Chang, MM Matzuk: ***Smad5* is required for mouse primordial germ cell development. *Mech Dev* 2001, 104: 61-67**
- 10
6. KD Tremblay, NR Dunn, EJ Robertson: **Mouse embryos lacking Smad1 signals display defects in extraembryonic tissues and germ cell formation. *Development* 2001, 128: 3609-3621**
7. Y Ying, GQ Zhao: **Cooperation of endoderm-derived BMP2 and extraembryonic ectoderm-derived BMP4 in primordial germ cell generation in the mouse. *Dev Biol* 2001, 232 (2): 484-492**
- 15
8. M Saitou, SC Barton, MA Surani: **A molecular programme for the specification of germ cell fate in mice. *Nature* 2002, 418: 293-300**
- 20
9. M Ginsburg, MHL Snow, A McLaren: **Primordial germ cells in the mouse embryo during gastrulation. *Development* 1990, 110: 521-528**

10. M Sato, T Kimura, K Kurokawa, Y Fujita, K Abe, M Masuhara, T Yasunaga, A Ryo, M Yamamoto, T Nakano: **Identification of PGC7, a new gene expressed specifically in preimplantation embryos and germ cells.** *Mech Dev* 2002, **113**: 91-94
- 5 11. AR Lewin, LE Reid, M McMahon, GR Stark, IM Kerr: **Molecular analysis of a human interferon-inducible gene family.** *Eur J Biochem* 1991, **199**: 417-423
12. RL Friedman, SP Manley, M McMahon, IM Kerr, GR Stark: **Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells.**
- 10 *Cell* 1984, **38**: 745-755
13. JM Kelly, CS Gilbert, GR Stark, IM Kerr: **Differential regulation of interferon-induced mRNAs and c-myc mRNA by alpha- and gamma- interferons.** *Eur J Biochem* 1985, **153**: 367-371
- 15 14. SS Evans, DB Lee, T Han, TB Tomasi, RL Evans: **Monoclonal antibody to the interferon-inducible protein Leu-13 triggers aggregation and inhibits proliferation of leukemic B cells.** *Blood* 1990, **76 (12)**: 2583-2593
- 20 15. SS Evans, RP Collea, JA Leasure, DB Lee: **IFN- α induces homotypic adhesion and Leu-13 expression in human B lymphoid cells.** *J Immunol* 1993, **150**: 736-747
16. DJ Hayzer, E Brinson, MS Runge: **A rat beta-interferon-induced mRNA: sequence characterization.** *Gene* 1992, **117 (2)**: 227-228
- 25

17. JK Pru, KJ Austin, AL Haas, TR Hansen: **Pregnancy and interferon-tau upregulate gene expression of members of the 1-8 family in the bovine uterus.** *Biol Reprod* 2001, **65 (5)**: 1471-1480
- 5 18. LE Reid, AH Brasnett, CS Gilbert, ACG Porter, DR Gewert, GR Stark, IM Kerr: **A single DNA response element can confer inducibility by both alpha- and gamma-interferons.** *Proc Natl Acad Sci USA* 1989, **86**: 840-844
19. GR Stark, IM Kerr, BRG Williams, RH Silverman, RD Schreiber: **How cells respond**
10 **to interferons.** *Annu Rev Biochem* 1998, **67**: 227-264
20. DP Barlow, BJ Randle, DC Burke: **Interferon synthesis in the early post-implantation mouse embryo.** *Differentiation* 1984, **27**: 229-235
- 15 21. M Kita, K Tanaka, K Shinmura, Y Tanaka, Y Liu, J Imanishi: **Expression of cytokines and interferon-related genes in the mouse embryo.** *C.R. Seances Soc. Biol. Fil.* 1994, **188 (5-6)**: 593-600.
22. KM Downs, T Davies: **Staging of gastrulating mouse embryos by morphological**
20 **landmarks in the dissecting microscope.** *Development* 1993, **118**: 1255-1266
23. DG Wilkinson, MA Nieto: **Detection of messenger RNA by *in situ* hybridisation to tissue sections and whole mounts.** *Methods Enzymol* 1993, **225**: 361-373
- 25 24. D Henrique, J Adam, A Myat, A Chitnis, J Lewis, D Ish-Horowicz: **Expression of a**

Delta homologue in prospective neurons in the chick. *Nature* 1995, **375**: 787-790

25. G Brady, NN Iscove: **Construction of cDNA libraries from single cells.** *Methods Enzymol* 1993, **225**: 611-623

REFERENCES FOR EXAMPLES 21 TO 25

- 5 1. Surani, M.A. Reprogramming of genome function through epigenetic inheritance. *Nature* **414**, 122-8 (2001).
2. Wu, X. et al. Zygote arrest 1 (Zar1) is a novel maternal-effect gene critical for the oocyte-to-embryo transition. *Nat Genet* **33**, 187-91 (2003).
3. Tong, Z.B. et al. Mater, a maternal effect gene required for early embryonic
10 development in mice. *Nat Genet* **26**, 267-8 (2000).
4. Howell, C.Y. et al. Genomic imprinting disrupted by a maternal effect mutation in the Dnmt1 gene. *Cell* **104**, 829-38 (2001).
5. Christians, E., Davis, A.A., Thomas, S.D. & Benjamin, I.J. Maternal effect of Hsf1 on reproductive success. *Nature* **407**, 693-4 (2000).
- 15 6. Gurtu, V.E. et al. Maternal effect for DNA mismatch repair in the mouse. *Genetics* **160**, 271-7 (2002).
7. Burns, K.H. et al. Roles of NPM2 in chromatin and nucleolar organization in oocytes and embryos. *Science* **300**, 633-6 (2003).
8. Sato, M. et al. Identification of PGC7, a new gene expressed specifically in
20 preimplantation embryos and germ cells. *Mech Dev* **113**, 91-4 (2002).
9. Saitou, M., Barton, S.C. & Surani, M.A. A molecular programme for the specification of germ cell fate in mice. *Nature* **418**, 293-300 (2002).

10. Goto, T. et al. Identification and characterisation of known and novel transcripts expressed during the final stages of human oocyte maturation. *Mol Reprod Dev* **62**, 13-28 (2002).
11. Looijenga, L.H. et al. Role of gain of 12p in germ cell tumour development. *Apmis* **111**, 161-71; discussion 172-3 (2003).
12. Mitsui, K. et al. The Homeoprotein Nanog Is Required for Maintenance of Pluripotency in Mouse Epiblast and ES Cells. *Cell* **113**, 631-42 (2003).
13. Chambers, I. et al. Functional expression cloning of nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell* **113**, 643-55 (2003).
- 10 14. Caricasole, A.A. et al. Human growth-differentiation factor 3 (hGDF3): developmental regulation in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours. *Oncogene* **16**, 95-103 (1998).
- 15 15. Spellman, P.T. & Rubin, G.M. Evidence for large domains of similarly expressed genes in the Drosophila genome. *J Biol* **1**, 5 (2002).
- 15 16. Ginsburg, M., Snow, M.H. & McLaren, A. Primordial germ cells in the mouse embryo during gastrulation. *Development* **110**, 521-8 (1990).
17. Fox, N., Damjanov, I., Martínez-Hernandez, A., Knowles, B.B. & Solter, D. Immunohistochemical localization of the early embryonic antigen (SSEA-1) in postimplantation mouse embryos and fetal and adult tissues. *Dev Biol* **83**, 391-8 (1981).
- 20 18. Johnson, M.H. & Everitt, B.J. *Essential reproduction*, xi, 377 (Blackwell Scientific, Oxford, 1988).
19. Montagutelli, X. Effect of the genetic background on the phenotype of mouse mutations. *J Am Soc Nephrol* **11 Suppl 16**, S101-5 (2000).

20. Lawson, K.A. et al. Bmp4 is required for the generation of primordial germ cells in the mouse embryo. *Genes Dev* **13**, 424-36 (1999).
21. Winnier, G., Blessing, M., Labosky, P.A. & Hogan, B.L. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. *Genes Dev* **9**, 2105-16 (1995).
22. Nothias, J.Y., Majumder, S., Kaneko, K.J. & DePamphilis, M.L. Regulation of gene expression at the beginning of mammalian development. *J Biol Chem* **270**, 22077-80 (1995).
23. Rugh, R. *The mouse : Its Reproduction and Development*, (Oxford University Press, Oxford England ; New York, 1990).
24. McLaren, A. & Michie, D. Studies on the transfer of fertilized mouse eggs to uterine foster-mothers. *J Exp Biol* **33**, 394-416 (1956).
25. Aravind, L. & Koonin, E.V. SAP - a putative DNA-binding motif involved in chromosomal organization. *Trends Biochem Sci* **25**, 112-4 (2000).
26. Chang, H. & Matzuk, M.M. Smad5 is required for mouse primordial germ cell development. *Mech Dev* **104**, 61-7 (2001).
27. Fukuda, M. et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. *Nature* **390**, 308-11 (1997).

20

Each of the applications and patents mentioned in this document, and each document cited or referenced in each of the above applications and patents, including during the prosecution of each of the applications and patents ("application cited documents") and any manufacturer's instructions or catalogues for any products cited or mentioned in each of the applications and patents and in any of the application cited

documents, are hereby incorporated herein by reference. Furthermore, all documents cited in this text, and all documents cited or referenced in documents cited in this text, and any manufacturer's instructions or catalogues for any products cited or mentioned in this text, are hereby incorporated herein by reference.

- 5 Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications
- 10 of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the claims.